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ABSTRACT
E2F transcription factors were originally identified as regulators of cell cycle and
cellular proliferation. In vivo mouse models have uncovered novel roles for these proteins
in different developmental processes. This dissertation examines the biological role of
E2F6 in mammalian development. E2F6 functions as a repressor of transcription in
concert with the polycomb group (PcG) proteins and chromatin modifiers. PcG proteins
regulate processes required for proper embryonic development and differentiation.
E2F6 interacts with core components of Polycomb Repressive Complex 1 (PRC1)
and participates in PcG-mediated repression of Hox genes. Hox genes are required for
correct patterning of the mammalian skeleton. Loss of E2f6 results in posterior axial
skeletal transformations. Mice deficient for both E2f6 and Bmil, a component of PRC1,
exhibit increased penetrance of axial skeletal transformations. Thus, E2F6 and Bmil
cooperate in the regulation of Hox genes and axial skeletal development. Bmi 1 also
represses transcription of the Ink4a-Arf locus, and it is consequently required to maintain
the proliferative and self-renewal properties of hematopoietic and neural stem cells.
However, E2F6 does not participate in the repression of the Ink4a-Arflocus. These
findings underscore the significance of the E2F6-Bmil interaction in vivo and suggest
that the Hox and Ink4a-Arfloci are regulated by somewhat different mechanisms.
In addition to axial skeletal transformations, E2f6' mice exhibit a suppressed
gliotic response after neural injury. Gliosis occurs in response to neurodegeneration,
ischemia, and neuronal cell death. This process provides neuronal protection by
restricting inflammation and regulating the concentration of molecules in the extracellular
environment. However, gliosis has potentially detrimental effects such as the inhibition
of axonal regeneration or the release of cytotoxic agents that trigger degeneration of
neighboring neurons. The molecular mechanisms required to initiate and sustain a gliotic
response are poorly understood. Gliosis is the focus of therapy for neurodegenerative
diseases and ischemia, and complete understanding of the mechanisms underlying this
process will lead to more effective therapies for neurodegenerative disease and ischemia.
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Chapter 1
Introduction
I. The E2F Family of Transcription Factors
The E2F transcription factors are classically described as key regulators of the cell
cycle and cellular proliferation. The cellular targets of E2F include cell-cycle regulators;
components of the DNA replication machinery; proteins involved in chromatin
modification, assembly, condensation, segregation; and nucleotide biosynthesis (some
classic E2F target genes are listed in Table 1). It is now clear that E2F also plays
important roles in development and disease. Many studies have linked the amplification
of E2Fs to various cancers (Oeggerli et al., 2006; Orlic et al., 2006; Hurst et al., 2007).
Further research has reported a requirement for different E2Fs in developmental
processes such as heart development (Cloud et al., 2002), axial skeletal development
(Courel et al., 2008), and embryonic development (Li et al., 2008).
1. Discovery and cloning of E2F
E2F was first identified in research based upon the observation that the
adenovirus E1A (early region LA) protein stimulates the transcription of several viral and
cellular promoters (Nevins, 1981). When Kovesdi et al. infected cells with E1A, they
discovered that the induction of transcription by E1A was dependent upon a cellular
factor, E2F (E2 factor) (Kovesdi et al., 1986). The induction was determined to be
independent of protein synthesis (Reichel et al., 1988). Subsequent research found that
ElA induces transcription by dissociating cellular E2F complexes. This dissociation
releases free E2F and activates E2F's transcriptional activity (Bagchi et al., 1990). Yee et
al. investigated the nature of E2F's induction of the E2 promoter. DNAse footprinting
Cell Cycle
Cdc2
Cdc25
E2fl
Cdk2
P107
pRB
CycE
CycA
B-myb
C-myc
CycD
Replication
PolA
Orcl 1
Mcm
Cdc6
PCNA
TK1
TOP2A
DHFR
Table 1: Classic E2F Target Genes
and DNA mutagenesis studies revealed two distinct E2F binding sites that were required
for transcription of the E2 protein (Yee et al., 1987). The discovery of an E2F binding
site allowed purification of E2F from crude extracts by chromatography and DNA
purification schemes. This purification yielded a 54kD protein that could bind to the E2F
consensus site and stimulate transcription in an in vitro reporter assay (Yee et al., 1989).
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Cell Division Cycle 2
Cell Division Cycle25
E2 promoter binding factor 1
Cyclin dependent kinase 2
Retinoblastoma-associated
protein homolog 107
Retinoblastoma-associated
protein
Cyclin E
Cyclin A
Cyclin D
DNA polymerase a
Origin recognition complex 1
Minichromosome maintenance
Cell division cycle 6
Proliferation cell nuclear antigen
Thymidine Kinase
Topoisomerase 2 a
Dihydrofolate reductase
References
(Tommasi and Pfeifer,
1995)
(Stevaux and Dyson, 2002)
(DeGregori et al., 1995a; Li
et al., 2008)
(Ren et al., 2002; Stevaux
and Dyson, 2002)
(Zhu et al., 1995)
(Ren et al., 2002)
(Botz et al., 1996) (Ohtani
et al., 1995; Geng et al.,
1996)
(Schulze et al., 1995)
(Zwicker et al., 1997)
(DeGregori et al., 1995a)
(DeGregori et al., 1995a)
(DeGregori et al., 1995a)
(Ohtani et al., 1996)
(Ren et al., 2002)
(Lavia and Jansen-Durr,
1999)
(DeGregori et al., 1995a)
(DeGregori et al., 1995a)
(Ren et al., 2002)
(Means et al., 1992; Wade
et al., 1992; Lavia and
Jansen-Durr, 1999)
In addition to E2Fs known role in the activation of viral genes, many scientists
hypothesized that E2F may have a similar cellular function. Indeed, many genes involved
in proliferation contain an E2F binding site, and E2F binding activity increases upon
serum stimulation of cells (Mudryj et al., 1990). This observation was the first step to
realizing E2F' s larger role in the control of proliferation and the cell cycle.
An important breakthrough in the elucidation of the mechanism of E2F's
transcriptional transactivation was the discovery that E2F is a cellular target of the
retinoblastoma protein, pRB (Chellappan et al., 1991; Chittenden et al., 1991; Kaelin et
al., 1991). pRB was known to control cell cycle and proliferation, but the mechanisms
were unknown (Chittenden et al., 1991; Kaelin et al., 1991). pRB and two related
proteins, p107 and p 130, are a family of transcription factors known as the pocket
proteins. The Rb-E2F interaction was the basis for cloning E2F. Helin and colleagues
screened a X expression library for cDNAs whose protein products had the ability to bind
the pocket region of pRB. They characterized a cDNA and its protein product that
interacts with pRB, binds to E2F recognition sequences, and transactivates the E2
promoter. Additionally, E1A disrupted the binding of this cDNA's protein and pRB
(Helin et al., 1992). This cDNA was ultimately determined to be the coding sequence of
E2F. The cloning of E2F was a milestone because it led to the discovery of an entire
family of E2F transcription factors that have the ability to either activate or repress
transcription. The E2F transcription factors work in concert with the pocket proteins to
control the entry and progression through the cell cycle.
2. The E2F/RB pathway
The pocket proteins are named based on their pocket-like structure. This pocket is
made of two sub-domains separated by a spacer (Ewen et al., 1991). Although the pocket
proteins have a similar structure, it is clear that they have different affinities for different
E2Fs. The activating E2Fs (E2F1, E2F2, and E2F3) associate almost exclusively with
pRB, and the repressive E2Fs (E2F4 and E2F5) associate mainly with p107 and p130.
pRB is often referred to as the restriction point switch of the cell cycle. Indeed,
the phosphorylation of pRB is a major determinant of whether the cell commits to a cell
cycle or re-enters a resting state (Go) (Bartek et al., 1996). A cell's ability to surpass the
restriction point when conditions for cell division are unfavorable is the basis for many
cancers. For this reason, it is important to know the factors and signaling pathways that
regulate this critical point in the cell cycle.
A resting cell in Go has low levels of pRB, low levels of the activating E2Fs, high
levels of cyclin dependent kinase inhibitors (CDKIs), and high levels of p130 (Weinberg,
1995; Dyson, 1998). The predominant complexes are p130-E2F4 and p130/p107-E2F5
(Dyson, 1998). This concerted gene expression pattern results in suppression of S-phase
and proliferation genes by two mechanisms. First, repressive pocket protein-E2F
complexes allow for active repression by recruitment of chromatin modifiers and histone
deacetylases that actively repress transcription. Second, pRB complexed with activating
E2Fs renders them functionally inactive and leads to a loss of transcriptional activation of
these genes (Figure 1) (Dyson, 1998; Trimarchi and Lees, 2002). The high levels of
CDKIs also suppress cell cycle progression by inhibiting the activity of any cyclin/cdk
complex that may be present (Dyson, 1998; Trimarchi and Lees, 2002).
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Figure 1: Transcriptional repression and activation by E2F.
E2F target genes are regulated in GdG, by a repressive complex consisting of repressive
E2Fs/DP, histone deacetylases (HDAC), and pocket proteins (pp). Upon mitogenic
stimulation, cycD/CDK complexes phosphorylate the pocket proteins. This
phosphorlylation leads to the disruption of pocket protein-E2F complexes, causing the
activating E2Fs to bind the promoters of cell cycle regulated target genes and activate
their transcription.
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Upon mitogenic stimulation, expression of cyclin Dl is induced (Matsushime et
al., 1991) and expression of CDKIs are reduced (Polyak et al., 1994). This gene
expression pattern shifts the CDKI-to-cyclin ratio and relieves inactivation of the cyclins
by the CDKIs (Weinberg, 1995). Cyclin D forms an active complex with cdk4 or cdk6
and then phosphorylates pRB. Phosphorylation of pRB causes the dissociation of E2F-
pRB complexes, and the activating E2Fs are now free to stimulate transcription of E2F-
target genes (Figure 1) (Weinberg, 1995; Dyson, 1998; Mittnacht, 1998). This first wave
of pRB phosphorylation and E2F transcriptional activity leads to increased transcription
of Cyclin E, an E2F-target gene. Cyclin E and cdk2 form an active complex that
hyperphosphorylates pRB, p107, and p130 (Weinberg, 1995; Dyson, 1998; Mittnacht,
1998). This results in disassembly of E2F-pocket protein complexes, a process that is
essential for entry into S-phase. Free, activating E2Fs now initiate transcription of S-
phase genes (Weinberg, 1995; Dyson, 1998; Mittnacht, 1998; Trimarchi and Lees, 2002).
Conversely, E2F4 and E2F5 lack a nuclear localization signal, and dissociation from the
pocket proteins results in their translocation from the nucleus and loss of transcriptional
repression of S-phase genes (Muller et al., 1997; Chestukhin et al., 2002). Activation of
gene expression, control of cyclin-cdk activity, and regulation of pRB phosphorylation
are critical for a cell's entry and committal to cell division.
3. Regulation, structural identity, and transcriptional activity of different E2Fs
The E2F transcription factors are essential for coordinated control of cell division
and proliferation. For this reason, it is not surprising that deregulation of E2F is the
hallmark of many cancers (Sherr, 1996). Understanding the regulation of E2F and the
mechanisms by which E2F confers control on the cell cycle is essential to studies in
cancer and other diseases.
To date, nine E2F and two DP (DRTF1 1olypeptide) proteins have been
identified. DP is the heterodimerization partner of E2F transcription factors, and it is
required for the DNA binding activity of E2Fs 1-6 (Bandara et al., 1993; Huber et al.,
1993). The E2F-DP complex creates a basic helix-loop-helix transcription factor that
recognizes the consensus DNA sequence 5'-TTTCGCGC-3' (Zheng et al., 1999;
Trimarchi and Lees, 2002). E2Fs 1-8 can be divided into subclasses based on their
structure, expression pattern, ability to bind pocket proteins, and transcriptional activity
(Figure 2). The E2Fs 1-6 share two structural domains: a DNA binding domain and a
dimerization domain (Trimarchi and Lees, 2002). The dimerization domain is necessary
for heterodimerization with a DP (DRTF1 polypeptide) subunit (Zheng et al., 1999). This
interaction is required for high affinity binding to E2F consensus sites (Slansky and
Farnham, 1996). E2F7 and E2F8, the newest members of the E2F family, have two
conserved DNA binding domains but lack a dimerization domain. Instead of
heterodimerizing with DP, E2F7 and E2F8 can heterodimerize or homodimerize with
themselves or with each other (Li et al., 2008). Exogenous expression of E2F7 or E2F8
can repress E2F target genes and block cell proliferation (de Bruin et al., 2003; Di
Stefano et al., 2003; Maiti et al., 2005).
Similar to E2F7 and E2F8, E2Fs 4-6 are also active repressors of transcription of
E2F-target genes (Muller et al., 1997; Verona et al., 1997; Trimarchi et al., 1998;
Giangrande et al., 2004). E2F4, E2F5, and E2F6 have all been shown to interact with
histone deacetylases, histone methylases, and other chromatin remodeling enzymes
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Figure 2: The E2F family of transcription factors.
The E2F transcription factors all contain a homologous DNA-binding region. The
activating E2Fs, E2Fs 1-3, each contain a nuclear localization signal (NLS), a marked
box, a dimerization region, and a pocket protein-binding region. The repressive E2Fs,
E2Fs 4-5, lack a NLS but have a nuclear export signal (NES). E2Fs 6-8 lack sequences
required for pocket protein binding and repress transcription through mechanisms
independent of the pocket proteins.
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associated with repressed chromatin (lavarone and Massague, 1999; Ogawa et al., 2002;
Attwooll et al., 2005). However, it is clear that E2F4 and E2F5 repress transcription in a
mechanism that is different from E2F6. E2F4 and E2F5 contain a pocket protein binding
domain and repress transcription through a pocket protein-E2F complex. Interaction of
E2F4-DP and E2F5-DP is also induces the nuclear localization of these complexes
(Trimarchi and Lees, 2002). E2F6 lacks a pocket protein binding domain and represses
transcription through its association with the polycomb group family of transcription
factors (discussed in more detail in following sections) (Trimarchi and Lees, 2002). E2F4
and E2F5 are present throughout the cell cycle (Slansky and Farnham, 1996), but they
accumulate in quiescent cells (Ikeda et al., 1996). In contrast, E2F6 levels increase as
cells enter the cell cycle and peak at mid Gl (Dahme et al., 2002). While the mechanisms
of repression and expression patterns of these two sub-groups of E2Fs differ, their
specific targets are overlapping, and it has been shown that E2F4 or E2F6 can
compensate for the loss of the other (Giangrande et al., 2004).
The last group of E2F transcription factors includes E2Fs 1-3. As with E2F4 and
E2F5, these E2Fs also have a pocket protein binding domain, a dimerization domain, and
a DNA binding domain (Helin, 1998; DeGregori, 2002; Trimarchi and Lees, 2002)
(Dyson, 1998). However, E2Fs 1-3 are potent activators of transcription and their
expression patterns are transcriptionally regulated throughout the cell cycle (Trimarchi
and Lees, 2002). The transcription of these E2Fs is induced in late G , and the gene
products accumulate at this time (Slansky and Farnham, 1996). E2Fs 4-5 require the
binding of a pocket protein to actively repress E2F-target genes. This repression is
achieved through interactions with pocket proteins and histone deacetylases. However,
E2Fs 1-3 must be dissociated from a pocket protein before they become transcriptionally
active (Sun et al., 2007). Overexpression of the activating E2Fs can induce quiescent
cells to re-enter the cell cycle and can override growth-arrest signals such as TGF(3 or
cyclin dependent kinase inhibitors such as p16, p21, or p27 (DeGregori et al., 1995a;
DeGregori et al., 1995b) (Schwarz et al., 1995; Mann and Jones, 1996). It is clear that
E2Fs 1-3 are potent activators of the cell cycle, and overexpression of an activating E2F
can induce transformation of primary cells (Johnson et al., 1994; Singh et al., 1994; Xu et
al., 1995). Similarly, loss of E2F1, E2F2, and E2F3 leads to a decrease in E2F-target
gene expression and a block in cell proliferation (Wu et al., 2001).
Together, the E2Fs and pocket proteins are critical for a cell's entry and
committal to cell division when conditions are favorable. The manner in which a cell
responds to unfavorable signals and aborts the cell division program is equally important.
When a cell undergoes DNA damage or oncogenic stress, a different program ensures
that a damaged or potentially cancerous cell does not undergo division. At the backbone
of this control are pl9ARF and p53. These proteins are the basis of the ARF-p53 tumor
surveillance network.
4. The Arf-p53 tumor surveillance network
pl 9ARF is one of the proteins encoded in the INK4A-ARF locus. The other protein,
p161NK 4 a, is a CDKI and inhibits cyclin/cdk complexes and subsequently the G,/S
transition (Sherr and Roberts, 1999). pl1 9 ARF is a tumor suppressor that responds to
abnormal proliferative or oncogenic signals. Its activation leads to cell cycle arrest or
apoptosis (Figure 3) (de Stanchina et al., 1998; Palmero et al., 1998; Radfar et al., 1998).
pl 9 ARF indirectly activates the tumor suppressor, p53, by binding and inhibiting Mdm2, a
repressor of p53 (Zhang et al., 1998). Upon activation of p53 by p19ARF, p53 increases the
levels of p21 (a CDKI) or activates Bax proteins. This leads to growth arrest or apoptosis
(Figure 3) (Lundberg and Weinberg, 1999).
The deregulation of INK4a-ARF or the E2F-RB pathway occurs in a significant
fraction of cancers. This suggests that circumvention of this pathway leads to cellular
transformation. Research of the complex mechanisms that control whether or not a cell
divides is critical to understanding the process of tumorigenesis.
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Figure 3: The Arf-p53 tumor surveillance pathway.
pl 9 ARF is activated by abnormal proliferative or oncogenic signals and is repressed in
normal proliferating cells by a polycomb group protein, Bmi 1. Activation of this pathway
results in cell cycle arrest or apoptosis.
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II. E2Fs in Development and Disease
The E2F transcription factors are key regulators of the cell cycle. However, in
vivo studies of the E2Fs in mouse models have uncovered roles for these proteins beyond
cell cycle control and proliferation. E2Fsl-8 have been deleted in mice, and analysis of
these mice has revealed overlapping and distinct roles for E2Fs in development,
differentiation, and disease.
1. The activating E2Fs: E2F1, E2F2, and E2F3
The activating E2Fs are critical for cellular proliferation. Deletion of E2fsl-3
results in severely impaired proliferation and cell cycle kinetics in cultured cells (Wu et
al., 2001). Disruption of activating E2Fs in mouse models reveals specific and
overlapping functions for these E2Fs. E2fl mutant mice are fully viable but exhibit
testicular atrophy, exocrine abnormalities, and a spectrum of tissue-specific tumors
(Yamasaki et al., 1996). Interestingly, overexpression of E2fl in mice leads to tumor
development as well, suggesting that E2F1 can act as a tumor suppressor and an
oncogene in vivo (Pierce et al., 1999). In contrast to E2fl mutant mice, E2f3 mutant mice
exhibit embryonic lethality in a pure genetic background and are born at one quarter the
expected frequency in a mixed genetic background. Although E2f3 mutant mice do not
develop tumors, they exhibit severe growth retardation and die prematurely from
congestive heart failure (Cloud et al., 2002). Analysis of E2fl;E2f3 compound mutant
mice revealed overlapping roles for these proteins. These mice had increased embryonic
lethality, growth retardation, and increased severity in testicular atrophy and congestive
heart failure. However, the compound mutant mice had no alteration in tumor incidence,
timing, or spectrum (Cloud et al., 2002). Recently, E2f3a and E2f3b-specific mutant mice
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have been developed. These mice are viable, and they have no histological abnormalities.
This suggests that E2f3a and E2f3b have overlapping roles in vivo. E2fl ;E2f3b mutant
mice are viable, and they have no tissue defects. E2fl;E2f3a mutant mice die perinatally
and exhibit a defect in cartilage development. (Danielian, Friesenhahn et. al, in press;
Appendix A). These studies reveal distinct roles for E2F1 and E2F3 in vivo.
E2J2 mutant mice, like E2fl, are born at the expected frequency. However, they
die prematurely from systemic autoimmune disease caused by enhanced T lymphocyte
proliferation (Murga et al., 2001) and hematopoietic defects (Li et al., 2003). E2fl;E2f2
mutant mice are viable, but diabetes causes a premature death. These mice exhibit a
reduction of size and cellularity of lymphoid organs, the testes, and salivary gland
(Iglesias et al., 2004). In this case, the resulting diabetes is caused by the combination of
the defect in hematopoiesis (caused primarily from E2J2 deletion) and exocrine
degradation (caused primarily by the E2fl deletion) (Li et al., 2003). E2F and E2F2
have distinct roles in vivo, but combinatorial loss of these two genes results in a novel
disease phenotype.
2. The repressing E2Fs: E2F4 and E2F5
E2F4 and E2F5 play similar roles in the repression of cell cycle genes. However,
in vivo studies revealed that these proteins have distinct roles in different developmental
programs. Mutation of E2f4 in mice uncovered a novel role for E2F4 in the control of
erythopoiesis. E2f4-' mice exhibited severe anemia, low red blood cell numbers,
macrocytosis, and Howell-Jolly bodies (Humbert et al., 2000). While the mature red
blood cells were abnormal, there was no defect detected in the immature erythrocytes,
suggesting that E2F4 is required for the late stages of erythrocyte maturation. These
mice have abnormal craniofacial development, abnormal development of the gut
epithelium, neonatal lethality, and growth retardation starting as early as E13.5 (Humbert
et al., 2000; Rempel et al., 2000). Neither the erythroid defect nor the resulting anemia is
the cause of the neonatal lethality. Instead, a defect in the development of cilia in the
nasal epithelium makes these mice unable to clear infectious agents, which results in
increased susceptibility to bacterial infections (Humbert et al., 2000; Danielian et al.,
2007). Similar to E2f4 mutant mice, E2f5 mutant mice have normal cell cycle kinetics.
These mice appear to develop normally prior to weaning age. After weaning, E2f5 mutant
mice developed ataxia, ruffled coats, and dehydration. Most of these mice died at around
six weeks of age due to hydrocephalus (excessive cerebrospinal fluid production) and
intracerebral hemorrhage. Lindeman et al. subsequently determined that E2F5 is
important for the regulation of secretion of cerebrospinal fluid (Lindeman et al., 1998).
While E2F4 or E2F5 can compensate for each other in vitro during the regulation of cell
cycle genes (Lindeman et al., 1998; Humbert et al., 2000), in vivo studies uncovered
novel roles for these proteins in different developmental pathways.
3. E2F6
Although E2F6 is a repressor of transcription, it lacks a pocket protein binding
domain and represses transcription through association with polycomb group proteins
(Trimarchi and Lees, 2002). E2F6 has been shown to interact biochemically with the
polycomb group proteins: EZH2, Bmil, Mel-18, RYBP, Ringla, and Ringlb (Trimarchi
et al., 2001; Ogawa et al., 2002; Attwooll et al., 2005). The polycomb group proteins
(discussed more in-depth in the next section) are repressors of homeobox (Hox) genes,
which control the anterior-posterior patterning of the developing embryo. Mice deficient
for E2F6 exhibit posterior transformations of the axial skeletons. These include: (1) a
T13-L1 transformation as evidenced by the absence or incomplete development of ribs
normally present on the thirteenth thoracic vertebra; and (2) a L6-S 1 conversion in which
the iliac bones associate with the sixth lumbar vertebra instead of the first sacral vertebra.
These mice survive to birth and live a normal life span. In vitro studies did not reveal any
cell cycle or proliferation defects (Storre et al., 2002; Courel et al., 2008). Further
analysis of E2f6 mutant mice revealed a defect in spermacyte development, but the defect
was not severe enough to affect fertility (Storre et al., 2002). Recently, unpublished data
suggests that E2F6 plays a role in the gliosis response of the brain after neuronal damage
(Chapter 3). E2f6-mutant mice exhibit a suppression of gliosis when they have brain
damage induced by Bmil-loss or injection of a neurotoxin (Chapter 3), but it is not clear
how E2f6 loss suppresses gliosis.
Beyond Hox gene regulation, little is known about which genes E2F6 controls. In
an attempt to understand more about the biological role of E2F6, some laboratories have
conducted microarrays or chromatin immunoprecipitation followed by CpG island
microarrays (Chip-Chip) to study which genes E2F6 regulates on a genome-wide scale.
Oberley et al. used Chip-Chip on human tumor cells and found that E2F6 regulates genes
involved in tumor suppression and maintenance of chromatin structure (Oberley et al.,
2003). Two other laboratories conducted cDNA microarray experiments with wildtype
and E2f6 mutant mouse embryonic fibroblasts (MEFs). These studies revealed that E2F6
is important for the repression of some meiotic (Smclf3 and STAG3) (Storre et al., 2005)
and testes-specific (ac-tubulin 3 and 7) genes (Pohlers et al., 2005). Although E2F6 is
widely expressed in most tissues, little is known about genes that E2F6 regulates in vivo.
While derepression of the testes-specific genes could explain the defect in spermacyte
development, the mechanism by which E2F6 regulates gliosis is still unknown.
4. E2F7 and E2F8
E2F7 and E2F8 are the most recent E2F family members to have been identified.
Homologous recombination techniques have been utilized to conditionally mutate each of
these genes in mice. E2f7 or E2f8 mutant mice are viable, and they display no
abnormalities. The E2J7;E2j8 compound mutant mice die as early as E11.5. These
embryos exhibit vascular defects, multifocal hemorrhages, and widespread apoptosis.
RNA analysis from these embryos revealed a substantial increase in the level of E2fl
mRNA. In wildtype cells, E2F7 and E2F8 occupy the promoter of E2fl and repress
transcription. The elevated level of E2F1 is due to a loss of direct repression by E2F7 and
E2F8. The massive apoptosis seen in the compound mutant animals is due to E2Fl
overexpression, p53 accumulation, and activation of the apoptotic response of the cell.
Microarray analysis from MEFs made from these embryos indicated a deregulation of
genes involved in stress responses to hypoxia, nutrient deprivation, and apoptosis (Li et
al., 2008). It is unclear whether deregulation of these genes is due to a direct loss of E2F7
and E2F8 transcriptional repression or whether it is due to an indirect consequence of the
apoptotic program that is activated in these cells. It will be interesting to learn what
tissue-specific abnormalities arise in these mice when E2J7 and E2f8 are acutely deleted
in different tissues.
5. Specificity of E2Fs in Development
It is clear the E2Fs have distinct and overlapping roles in development. While this
is not surprising, it still raises the question of where the specificity arises among different
functional groups of E2Fs. There is some evidence to suggest that specificity arises from
the spatial and temporal regulation of individual E2F family members. For example,
E2Fs 4 and 5 exhibit disparate embryonic expression patterns. E2F4 is expressed early in
proliferating cells and the epithelium, while E2F5 is mainly expressed in terminally
differentiating or differentiated cells (Lindeman et al., 1998; Humbert et al., 2000;
Rempel et al., 2000). In fact, most E2Fs exhibit tissue and cell-type specific expression
patterns during development (Dagnino et al., 1997). This implies that, while E2Fs in the
same functional group may be able to compensate for one another, diverse expression
patterns may prevent them from doing so in certain tissues. Another theory is that
different combinatorial interactions achieve the specificity of function seen in
developmental processes. For example, in a yeast two-hybrid screen for E2F3-specific
interacting partners, TFE3 was found to bind specifically to E2F3 but not other activating
E2Fs. The E2F3-TFE3 complex synergistically controls transcription of the p68 gene
(Giangrande et al., 2003). It is likely that E2F specificity is achieved by a combination of
these two mechanisms.
III. Regulation of Hox Genes by Polycomb Group Proteins.
Polycomb group proteins were first characterized in metazoan development as
regulators of segment identity. A central question in this field was how embryonic cells
first acquired and subsequently maintained unique positional identities. Through genetic
analysis and mutational studies in Drosophila, the answer came with the discovery of
Polycomb group (PcG) genes and their transcriptional targets, the homeotic genes (Hom).
These genes were determined to be important regulators of cellular identity in
Drosophila. The PcG genes and Hom genes (called Hox in vertebrate systems) are highly
conserved in mammals, and these genes play a similar functional role. It is clear that PcG
genes have roles beyond their transcriptional regulation of the Hox genes. Mutations of
PcG proteins in mammalian systems lead to deregulation of Hox genes and patterning
defects as well as other developmental abnormalities.
1. The Regulation of Horn genes in Drosophila
The Drosophila embryo is composed of segmented units, or a repeated pattern of
elements along the anterior-posterior axis. This metameric organization is established
within the first two hours following fertilization. This process requires coordinated
expression of two groups of genes: the segmentation genes and the homeotic genes
(Hom) (Akam, 1987). The segmentation genes are the first detectable zygotically active
genes and are divided into three classes based on their mutated phenotypes. The first
group consists of gap genes whose mutations cause multiple adjacent segments to be
missing from the embryo (Nusslein-Volhard and Wieschaus, 1980; Qian et al., 1993;
Shimell et al., 1994). The second class of genes includes the pair-rule genes whose
mutations cause alternate segment-size units to be missing (Nusslein-Volhard and
Wieschaus, 1980; Qian et al., 1993). The third type of gene is the segment polarity genes
whose mutations lead to a deletion in part of every segment and a replacement of the
deleted part with a mirror image of the remaining structure (Nusslein-Volhard and
Wieschaus, 1980; Hooper and Scott, 1989; Perrimon and Smouse, 1989). Correct spatial
and temporal expression of the Hom genes is required for segment identity in the
developing Drosophila embryo. The segmentation genes serve to initiate a
transcriptionally active (by the pair-rule genes) or repressed (by the gap genes) state of
the Hom genes (Scott and Carroll, 1987). Early in embryogenesis (about four hours),
expression of the segmentation genes disappear (Akam, 1987), and other regulatory
mechanisms are required to maintain the transcriptional program created by these genes.
The polycomb group proteins and trithorax group proteins maintain the
transcriptional state of the Hom genes initiated by the segmentation genes. PcG proteins
maintain repression of the Hom genes while trithorax group proteins maintain their
activation. Mutations of PcG proteins lead to a derepression of Hom genes and segments
that differentiate into structures characteristic of posterior segments (Struhl and Akam,
1985; Simon et al., 1992; Chiang et al., 1995). Ectopic expression or mutation of Hom
genes in Drosophila changes the identity of the segment and leads to the formation of
structures characteristic of a different segment (Kaufman et al., 1990; Pattatucci and
Kaufman, 1991; Pattatucci et al., 1991). Polycomb and trithorax group proteins play a
vital role in transcriptional regulation of the homeotic genes in Drosophila during
embryonic development.
2. Regulation of Hox genes in mammals.
The Hox genes play a similar role in mammalian development. Hox genes are
required for patterning of the body plan and development of the axial skeleton. Similar to
Drosophila, the mammalian axial skeleton develops from metameric units called somites.
During gastrulation, a subpopulation of the mesoderm that resides around the neural tube
(paraxial mesoderm) is formed. Somites form from blocks of cells that separate from the
paraxial mesoderm in a process called "initial segmentation." The dorsal portion of the
somite eventually becomes the dermomyotome. The ventral portion becomes the
sclerotome, which contains stem cells that eventually give rise to the axial skeleton. In a
process called "resegmentation," the sclerotome cells segregate into rostral and caudal
compartments. The rostral and caudal halves then fuse with their neighbor to form a
vertebra (reviewed in (Yamaguchi, 1997; Saga and Takeda, 2001).
Hox genes regulate the patterning of the mammalian axial skeleton. While
Drosophila have only two clusters of Hox genes (Antennapedia complex - ANT-C and
bithorax complex - BX-C), mammals have thirty-nine Hox genes arranged in four
clusters (HoxA, HoxB, HoxC, and HoxD) and thirteen paralogous groups (Hoxl-13). The
expression of Hox genes is described as "temporal and spatial colinearity." This term
refers to how the timing of expression during embryonic development correlates with the
spatial location of the Hox genes within each cluster. The 3' genes (HoxAl, HoxB1 etc...)
are expressed the earliest and are detected at seven days post-conception (dpc) (Dolle et
al., 1989; Izpisua-Belmonte et al., 1991). Mutations in 3' Hox genes exhibit phenotypes
in the anterior region of the axial skeleton, while mutations in 5' Hox genes exhibit
phenotypes in the posterior region (Condie and Capecchi, 1993; Davis and Capecchi,
1994). Due to the redundancy within paralogous Hox genes, mutation of any single Hox
gene do not affect viability and result in relatively minor phenotypes. Mutations of the
Hox3 through Hoxll genes cause defects in the axial skeleton (Chisaka and Capecchi,
1991; Le Mouellic et al., 1992; Condie and Capecchi, 1993; Jeannotte et al., 1993; Davis
and Capecchi, 1994; Rancourt et al., 1995; Suemori et al., 1995; Chen and Capecchi,
1997; van den Akker et al., 1999; van den Akker et al., 2001; McIntyre et al., 2007).
Paralogous mutations have been constructed for many of the Hox gene groups. These
mutations lead to synergistic and severe axial skeletal phenotypes. For example,
mutations of the Hox9 paralogous group have anterior transformations of the thoracic
vertebrae, such that there are thirteen or fourteen ribbed vertebra attached to the sternum
instead of the normal seven (McIntyre et al., 2007). Mutation of an entire cluster has a
less severe phenotype than paralogous mutations. The exception to this is HoxB, whose
mutation results in a severe sternal phenotype (Medina-Martinez et al., 2000). This is
probably due to the fact that HoxB contains Hox5-9, all of which are important for the
patterning of the sternum. The other Hox clusters have only two to four members of
Hox5-9. It is clear from these studies that coordinated expression of the Hox genes is vital
to proper development of the mammalian embryo. Thus, it is important to understand the
mechanisms underlying the regulation of these genes.
Hox gene regulation in mammals is more complex than in Drosophila. Gap or
pair-rule type regulation has not been identified in mammals. Instead, Hox regulation is
initiated by a variety of transcription factors, signaling molecules, and polycomb group
proteins. During development, FGF (Ciruna and Rossant, 2001; Dubrulle and Pourquie,
2004), WNT (Aulehla et al., 2003; Forlani et al., 2003) and retinoic acid (Boncinelli et
al., 1991; Krumlauf, 1994) gradients are early regulators of Hox genes. These molecules
act by signaling to Cdx genes, which then directly stimulate the transcription of Hox
genes in a dosage dependent manner (Subramanian et al., 1995; Pownall et al., 1996;
Charite et al., 1998; Isaacs et al., 1998; Houle et al., 2003; Gaunt et al., 2004). Mutations
of Cdx genes, hypomorphs of Fgfrl, and hypomorphs of Wnt3 lead to a deregulation of
Hox genes and axial skeletal transformations (Partanen et al., 1998; Ikeya and Takada,
2001; van den Akker et al., 2002). The mechanisms described above serve to initiate
transcriptional activation of the Hox genes. Transcriptional repression of these genes
early in embryonic development requires the actions of multiprotein polycomb repressive
complexes.
3. Polycomb Repressive Complexes
Two core Polycomb repressive complexes (PRCs) have been purified from
Drosophila and Hela cells and were found to have many of the same homologous
proteins. PRC2, which is required for the initiation of Hox gene repression in mammals,
contains the proteins EZH2, Suzl2, and EED (Cao et al., 2002; Kuzmichev et al., 2002;
Muller et al., 2002). This complex initiates a heritable, repressive state of Hox genes
through modifications of the chromatin structure. EZH2, a core component of the PRC2
complex methylates histone H3 at lysine 27 (Cao et al., 2002; Czermin et al., 2002;
Kuzmichev et al., 2002; Muller et al., 2002). In some cases, his methyl mark serves to
recruit PRC1. However, it has also been shown that PRC1 is recruited in the absense of
PRC2 (Schoeftner et al., 2006). The PRC1 core complex contains the proteins Bmil,
Ringla, Ringlb, HPH, HPH2, HPC2, HPC3, and Scmhl (Saurin et al., 2001; Levine et
al., 2002). Most importantly, HPC, a homologue of the Drosophila polycomb (Pc)
protein, directly binds to methylated histone H3 at lysine 27 through a highly conserved
chromodomain (Cao et al., 2002; Muller et al., 2002). PRC2 initiates Hox gene
repression, and PRC1 maintains the repression throughout development. Mice deficient
for a component of the PRC2 complex die early in development by 7 dpc (Faust et al.,
1995; O'Carroll et al., 2001; Pasini et al., 2004). In contrast, most PRC1 mice exhibit no
reduction in viability and display axial skeletal transformations (van der Lugt et al., 1994;
Takihara et al., 1997; del Mar Lorente et al., 2000; Tokimasa et al., 2001). The exception
to this is Ringlb (Ring2) deficient mice. These mice arrest in gastrulation, and they are
predicted to have a proliferation defect. An upregulation of the Ink4a-Arf locus is
observed, and mice deficient for both Ringlb and Ink4a-Arf exhibit a partial rescue of the
early embryonic lethality (Voncken et al., 2003).
IV. Polycomb Group Proteins in Development and Disease.
Polycomb group proteins are required for correct development and patterning of
the mammalian embryo. Mutation or misexpression of these genes causes a wide
spectrum of defects. These include early embryonic lethality, axial skeletal
transformations, and a variety of cancers. PcG mutants also exhibit impairment in
hematopoiesis, cell cycle control, senescence, X-inactivation, stem cell maintenance, and
differentiation. Described below are some of the key players of polycomb group
complexes and polycomb group proteins that have been found to biochemically interact
with E2F6.
1. PRC2: EZH2, EED, Suzl2
The PRC2 complex plays a vital role in the initiation of a developmental program
that is required for patterning of the mammalian embryo. The components of the PRC2
complex are required for early embryonic development, and mice deficient for these
genes die by seven days post-conception (Faust et al., 1995; O'Carroll et al., 2001; Pasini
et al., 2004). EZH2 is the component of the PRC2 complex that methylates histone H3 at
lysine 27. Loss of EZH2 results in a loss of this methylation mark in early zygotes
(Erhardt et al., 2003) and severely compromises the proliferation of embryonic stem (ES)
cells. Attempts to derive ES cells from blastocysts generate non-ES-like cells that
become apoptotic or necrotic (O'Carroll et al., 2001). Alternatively, overexpression of
EZH2 increases the proliferative capacity of primary B cells (Visser et al., 2001) and
bypasses cellular senescence in MEFs (Kamminga et al., 2006). EZH2 is strongly
expressed in highly proliferative, undifferentiated cells (Visser et al., 2001). As cells
31
differentiate, expression of EZH2 is developmentally downregulated, and overexpression
of EZH2 in undifferentiated cells prevents them from differentiating (Caretti et al., 2004).
One hypothesis is that EZH2 plays a role in maintaining a cell's "stemness" during
development. In support of this hypothesis, overexpression of EZH2 in hematopoietic
stem cells prevents stem cell exhaustion when bone marrow is serially transplanted
(Kamminga et al., 2006). EZH2 is also found to be overexpressed in a variety of
cancerous cells including lymphoma (Visser et al., 2001), bladder cancer (Arisan et al.,
2005), breast carcinomas, prostate cancer (Varambally et al., 2002; Kleer et al., 2003),
and bronchial squamous cell carcinomas (Breuer et al., 2004). The precise mechanism of
EZH2's involvement in cancer is unknown. An attractive model is that overexpression of
EZH2 may be trapping the cell in a highly proliferative, stem cell-like state. The result is
a block in appropriate differentiation and an induction of abnormal proliferation.
EED and Suzl2 also play a role in differentiation and early embryonic
development. Mice with a hypomorph for Eed exhibit posterior transformations along the
AP axis (Schumacher et al., 1996) and a deregulation of Hox genes (Wang et al., 2002),
consistent with a role for this protein in Hox gene regulation. Eed homozygous mutant
mice display a defect in embryonic ectoderm growth, an absence in axial structures, and
early embryonic lethality (Niswander et al., 1988; Faust et al., 1995). Unlike EZH2
mutant ES cells, ES cells from Eed or Suz12 mutant blastocysts are viable, but they lack
methylation of histone H3 at lysine 27 (Montgomery et al., 2005; Boyer et al., 2006;
Pasini et al., 2007). Suzl2 plays an essential role in promoting differentiation. ES cells
and embroid bodies deficient for this gene fail to differentiate properly (Pasini et al.,
2004; Pasini et al., 2007). Additionally, a Suzl2 point mutation that causes aberrant
mRNA splicing results in an increase in the number of multipotent hematopoietic
progenitors and enhances hematopoietic stem cell activity (Majewski et al., 2008). These
results present a requirement for Suzl2 and the PRC2 complex in differentiation of
different populations of progenitor cells.
2. Bmil
Bmil was first identified as an oncogene that cooperates with the Ept-myc
transgene in B-cell lymphoma (Haupt et al., 1991; van Lohuizen et al., 1991). Bmil is
homologous to the Drosophila gene posterior sex combs, (Adler et al., 1991; Brunk et
al., 1991) and it has been found to be a part of the core PRC1 complex involved in
maintenance of gene repression (Lewis, 1978; Paro, 1990; Zink et al., 1991; Saurin et al.,
2001; Levine et al., 2002). Bmil is highly expressed progenitor cell populations. Adult
tissues have a low level of Bmil RNA with the exception of the thymus, heart, brain, and
testes (van Lohuizen et al., 1991). Mice deficient for this protein exhibit a variety of axial
skeletal transformations, which is consistent with a role for Bmil in Hox gene repression.
The transformations include (van der Lugt et al., 1994; Courel et al., 2008):
(1) E - an extra piece of bone rostral to the first cervical vertebra, C1
(2) C1-C2 conversion in which the second cervical vertebra is transformed to the
first cervical vertebra and has an axis-like appearance
(3) C7-T1 conversion evidenced by the presence of ribs on the seventh cervical
vertebra, which then fuse with ribs at the first thoracic vertebra or connect directly
to the sternum
(4) T7-T8 conversion resulting in six vertebrosternal ribs instead of seven
(5) T13-L1 conversion in which there is an absence or incomplete development of
ribs normally present on the thirteenth thoracic vertebra and
(6) L6-S 1 conversion demonstrated by an association of iliac bones with the sixth
lumbar vertebra instead of the first sacral vertebra.
In addition to axial skeletal transformations, Bmil-mutant mice display a variety of other
defects, indicating that Bmi 1 has roles beyond the maintenance of repression of the Hox
genes.
Bmil-mutant mice are born at expected frequency but are smaller in size and
selectively cannibalized shortly after birth. Approximately 50% survive to adulthood (van
der Lugt et al., 1994; Courel et al., 2008). In addition to axial skeletal transformations,
these mice also display defects in hematopoiesis, the central nervous system, and the
peripheral nervous system (van der Lugt et al., 1994; Jacobs and van Lohuizen, 2002). In
the hematopoietic system, there is a loss of mature T and B cells, hypocellularity of the
bone marrow, decreased spleen size, and an involuted thymus (van der Lugt et al., 1994;
Lessard and Sauvageau, 2003). The neurological defects in the Bmil mutant mice include
an ataxic gait; seizures; hypocellularity of the molecular and granular layers of the
cerebellum; and astrogliosis in the cortex and cerebellum of the brain (van der Lugt et al.,
1994; Molofsky et al., 2003; Leung et al., 2004; Zencak et al., 2005). The neurological
and hematopoietic defects can be partially attributed to a deficiency in the proliferation
and self-renewal capacity of the stem cells in these compartments (Lessard and
Sauvageau, 2003; Park et al., 2003; Molofsky et al., 2005).
The proliferation defects observed in vivo are consistent with a role for the PcG
proteins in the control of the cell cycle. Indeed, mouse embryonic fibroblasts (MEFs)
deficient for Bmil have impaired proliferation properties and undergo premature
senescence (Core et al., 1997; Jacobs et al., 1999b; Courel et al., 2008). Bmil is a
repressor of the Ink4a-Arf, and the cell cycle defects in the Bmil /' MEFs result from a
derepression of this locus (Jacobs et al., 1999b). Mice mutant for Bmil and Ink4a-Arf
have a partial rescue of the neural and hematopoietic defects. BmilP;Ink4a-Arf' mice
exhibit a cerebellum that is comparable in size to wildtype mice, and the number of
thymocytes and splenocytes is now 50-70% of wildtype levels. The proliferative and
senescent defects of MEFs deficient for Bmil are fully rescued in Bmil'l;Ink4a-Arf'
MEFs (Jacobs et al., 1999b). These studies clearly show that Bmil plays a vital role in
the INK4A-ARF tumor surveillance pathway. Therefore, it is not surprising that Bmil is
deregulated in a variety of cancers. These cancers include: high grade B-cell Non-
Hodgkin lymphomas (Bea et al., 2001), breast carcinomas (Dimri et al., 2002), non-small
cell lung cancers (Vonlanthen et al., 2001), medulloblastomas (Leung et al., 2004), and
human colorectal cancers (Kim et al., 2004). Recent studies implicate Bmil in the
proliferation of bronchiolalveolar stem cells and a requirement for Bmil in lung
tumorigenesis (Dovey et. al, in press). It is clear that Bmil and INK4a-ARF are
important for the maintenance and proliferation of different populations of stem cells, and
deregulation of these genes can cause inappropriate proliferation and cancer.
3. Mel-18
Mel-18 is a PcG protein that is 70% identical to Bmil (Tagawa et al., 1990;
Goebl, 1991). Like the Bmil mutant mice, Mel-18 mutant mice are growth retarded and
defective in hematopoiesis. These mice also die in a similar time frame as the Bmil
mutant mice (Akasaka et al., 1996). The hematopoietic defects of Mel-18 mutant mice
include a defect in B-cell proliferation and maturation, impaired expansion of the most
immature T progenitor cells, severe thymic atrophy, and an impairment in the self-
renewal and proliferation of the hematopoietic stem cells (Akasaka et al., 1996; Akasaka
et al., 1997; Miyazaki et al., 2005). Mel-18/' mice also exhibit posterior axial skeletal
transformations similar to those found in Bmil deficient mice. These include E, C 1-C2,
C7-T1, T13-L1, and L6-S1. These mice also have a C2-C3 transformation marked by the
lack of the odontoid process from the C2 vertebra and an S4-Cal transformation in which
the fourth sacral vertebra looks like the first caudal vertebra (Akasaka et al., 1996). It is
apparent that Bmi 1 and Mel-18 have overlapping functions in vivo. However, there are
no indications that Mel-18 is a regulator of the Ink4a-Arf locus or that it plays a role in
the proliferation of neural or lung stem cells.
4. Ringl/Ringla and Ring2/Ringlb
Ring 1 a and Ring lb were first characterized on the basis of their interaction with
M33 in a yeast two-hybrid screen (Schoorlemmer et al., 1997). The two genes are both
found to be in the PRC 1 core complex, and they interact with many other PcG proteins
(Satijn et al., 1997; Schoorlemmer et al., 1997; Hemenway et al., 1998; Satijn and Otte,
1999; Levine et al., 2002). Ringla deficient mice are viable, but they display axial
skeletal transformations (del Mar Lorente et al., 2000). Interestingly, the skeletal
transformations in Ringla mutant mice are anterior, while all other mutant mice for
PRC 1 components have posterior transformations (van der Lugt et al., 1994; Akasaka et
al., 1996; Takihara et al., 1997). The exception to this is M33 mutant mice, in which most
of the axial skeletal transformations are posterior except for an anterior transformation of
C2-Cl (Core et al., 1997; Katoh-Fukui et al., 1998). The anterior axial skeletal
transformations of Ringla mutant mice include (del Mar Lorente et al., 2000):
(1) an abnormal Cl and C2
(2) a C2-C1 transformation characterized by a broadening of the neural arch
(3) a T3-T2 transformation in which the prominent spinous process normally
found on T2 is now present on T3
(4) a T8-T7 transformation marked by the presence of eight vertebrosternal ribs
instead of seven and
(5) a L1-T13 transformation evidenced by rudimentary ribs on L1.
Mice overexpressing Ringla display many of the same transformations, including the C2-
C1, the T8-T7, and the L1-T13. These mice also have a T10-T9 transformation (dorsal
cartilage normally found on T10 is now present on T9) (del Mar Lorente et al., 2000).
Expression of Ringla in the embryo is limited to the central nervous system at E8.5. At
E13.5 it is found in the central and peripheral nervous system, and at E15.5 it is also
found in the thymus and epithelial cell types. In the adult mouse, Ring l a is expressed in
differentiated tissues (Schoorlemmer et al., 1997). The skeletal transformations of Ringla
are consistent with its role as a member of PRC 1.
In contrast to Ringla mutant mice, Ringlb mutant embryos arrest early in
embryogenesis during gastrulation (Voncken et al., 2003). Ringlb expression is found
early in the blastocyst and embryonic stem cells (Voncken et al., 2003). A Ringlb
hypomorph mutant mouse is viable, but it displays posterior axial skeletal
transformations. These include (Suzuki et al., 2002):
(1) a supraoccipital bone-Cl transformation in which there are ectopic bones on
the Cl vertebra
(2) a C1-C2 transformation
(3) a C2-C3 transformation in which C2 lacks the odontoid process
(4) a C7-T1 transformation
(5) a T1-T2 transformation in which the prominent spinous process of T2 is now
present on T1
(6) a T7-T8 transformation
(7) a T13-L1 transformation
(8) a L6-S 1 transformation and
(9) a S4-Cal transformation.
These skeletal transformations were accompanied by a deregulation of Hox genes
(Suzuki et al., 2002). The diversity in the phenotypes and viability of the Ringla and
Ringlb mutant mice suggests that these two highly related proteins have different
functions in vivo.
Little was known about the mechanism of Ringla and Ringlb until de Napoles et
al. found that these proteins have catalytic E3 ubiquitin ligase activity towards histone
H2A at lysine 119. Ring lb maintains global H2A ubiquitination in ES cells, and both
Ringla and Ringlb can ubiquitinate histone H2A on the inactive-X chromosome (de
Napoles et al., 2004; Cao et al., 2005). The big question was whether the ubiquitin
chromatin mark contributes to repression or whether it has another function. To answer
this question, Cao et al. found evidence that this chromatin mark participated in
repression by PRCs and that H2AK 119 ubiquitination is downstream of histone H3 lysine
27 methylation (Cao et al., 2005). Recent evidence suggests the ubiquitin mark of histone
H3 interferes with the processivity of the RNA polymerase. This provides a direct
mechanism by which histone H3 ubiquitination represses transcription by interfering with
the RNA polymerase (Stock et al., 2007).
5. RYBP
RYBP (Ring l and YY 1 Binding Protein) was cloned as an interactor with Ring la.
RYBP also interacts with many other PcG proteins and E2Fs 2, 3, and 6 (Garcia et al.,
1999; Schlisio et al., 2002). Recent published and unpublished results provide insight
into the mechanism in which RYBP may contribute to polycomb silencing and X-
inactivation. RYBP contains an Np14 zinc finger (NZF) and binds to ubiquitinated
histone H2A in vivo (Arrigoni et al., 2006). Additionally, RBYP co-localizes with Ringla
at the inactive-X chromosome (Arrigoni et al., 2006). Experiments from Professor Jackie
Lees's laboratory identified Suv4-20 in a yeast two-hybrid assay as a possible interactor
of RYBP. This protein, similar to EZH, contains a SET domain and can tri-methylate
histone H4 at lysine 20 (Schotta et al., 2004). This methyl mark, which is downstream of
the methylation of histone H3 lysine 27, is found at pericentric heterochromatin and the
inactive-X chromosome (Plath et al., 2003; Silva et al., 2003; Schotta et al., 2004). One
possible mechanism is a sequential recruitment of histone modifications that contribute to
a highly condensed state of chromatin. RYBP may serve as a bridging protein between
the complex that ubiquitinates histone H2A and the complex that methylates histone H4
at lysine 20. The interaction between RYBP and Suv4-20, however, has not been
confirmed, and this mechanism is highly speculative.
Rybp mutant embryos die early during embryonic development at E5.5, indicating
that RYBP is important during postimplantation. Rybp"' and chimeric mice have many
defects of the central nervous system and in ocular development. These include
exencephaly due to defective neural tube closure, chaotic forebrain outgrowth, retinal
coloboma, ventral rotation of the lens, and an abnormal separation of the lens vesicle
from the surface of the ectoderm. There is no indication that Rybp ÷' mice display any
axial skeletal transformations or deregulation of Hox genes. Clearly, Rybp is essential for
proper embryonic and central nervous system development, and it will be important to
study the exact mechanism and the significance of RYBP's ubiquitin binding activity.
6. Synergy between PcG proteins
Compound mutants of PRC1 components have been generated in mice and flies.
Despite the fact that these proteins participate in the same complex, the result is often an
exacerbation of the skeletal and developmental defects (Bel et al., 1998; Akasaka et al.,
2001; Kwon et al., 2003; Courel et al., 2008). This result emphasizes the partial
functional redundancy of some PRC1 components. The synergy between PRC1
components is best studied in Bmil mutant mice. These mice exhibit posterior axial
skeletal transformations as well as severe developmental defects. The posterior axial
skeletal transformations are due to deregulation of Hox genes, and the developmental
defects are due to a deregulation of the Ink4a-Arf locus and impaired stem cell
proliferation and maintenance.
Compound mutants of Bmil, a core component of PRC 1, and other PRC1 proteins
show a clear synergy in Hox gene regulation. Mice doubly deficient for Bmil and Mel] 8
or M33 exhibit exacerbated defects in axial skeletal development. Significantly, the
severity of these defects increases upon a decrease in the PcG gene dosage. These
compound mutant mice also show an increased anterior shift in the boundaries of some
Hox genes in the embryos (Bel et al., 1998; Akasaka et al., 2001). Mice doubly deficient
for Bmil and E2f6 have also been generated. There is an increased penetrance of some of
the axial skeletal transformations, and this is accompanied by a further derepression of
Hox genes. E2F6 was also found to occupy a subset of Hox gene promoters that Bmi 1
occupies (Courel et al., 2008). Bmil loss in combination with mutation of E2f6, Mel-18,
or M33 causes further deregulation of Hox genes and exacerbated axial skeletal defects.
These exemplified genetic interactions underscore the documented biochemical
interactions for these proteins and provide a biologically relevant role for this interaction.
E2F6, M33, and Mel-18 synergize with Bmil in axial skeletal development, but
there is no conclusive evidence to suggest that these proteins cooperate with Bmil in the
regulation of Ink4a-Arf. Mice doubly deficient for Bmil and Me118 or M33 die during
embryogenesis (Bel et al., 1998; Akasaka et al., 2001). The Bmil;M33 compound mutant
mice exhibit increased apoptosis in the embryo, suggesting that there may be enhanced
deregulation of the Ink4a-Arf locus. These mice did have a ten-fold increase in Arflevels
compared to wildtype littermates, but the levels in Bmil mutant embryos were not
reported in this analysis. It is inconclusive whether the levels of Arf are further increased
in the compound mutant embryos when compared to the Bmil mutant embryos or
whether the level of derepression seen was solely due to loss of Bmil. No analysis was
done of cells from these mice, and it is unknown whether loss of Mel-18 in Bmil-mutant
mice enhances the proliferation defect of primary cells (Akasaka et al., 2001). In the case
of the Bmil;M33 compound mutant mice, no analysis was done of the Ink4a-Arflocus,
apoptosis, or proliferation, and there was no suggestion as to why these mice died
significantly earlier than the Bmil or M33 single mutants (Bel et al., 1998).
In contrast to M33 and Me1J8, loss of E2f6 in Bmil mutant mice does not alter the
lifespan of these mice. In this case, an interaction between E2F6 and Bmi 1 in the
regulation of Ink4a-Arf was well studied. Compound mutants, as well as intermediate
genotypes, were analyzed for exacerbated hematopoietic and neural phenotypes. There
was no significant difference between the Bmil-mutant and Bmil;E2f6 compound mutant
mice. MEFs from these mice did not have enhanced proliferative defects or enhanced
deregulation of Bmi 1 or E2F6 target genes. The exception to this is a subset of the Hox
genes, in which the penetrance was increased in Bmil ';E2f6' - mice compared to Bmil /'
mice. Additionally, Bmil, but not E2F6, was found to occupy the promoter of Arfin
wildtype embryonic stem cells. These data clearly indicate that E2F6 does not play a role
in the regulation of the Ink4a-Arf locus (Courel et al., 2008).
These studies of the genetic interactions between PRC1 components consistently
show that loss of one or two PRC1 components results in a deregulation of some Hox
genes. This result underscores the complexity of Hox gene regulation and suggests that
there may be PRCs of different compositions that regulate different Hox genes. Many of
these proteins are involved in modification of histones and chromatin compaction. It is
likely that these chromatin marks play an important role in the regulation of Hox and
other genes. It will be important to do a more detailed analysis of these chromatin marks
and the complexes that initiate and maintain them.
V. Reactive Gliosis
The E2F proteins are classically known for their role in regulating the cell cycle,
however, these proteins play other roles in development and disease. In this thesis, I have
described a novel requirement for E2F6 in reactive gliosis. Reactive gliosis forms in
response to brain injury and central nervous system pathologies including Parkinson's
disease, Alzheimer's, stroke, amyotrophic lateral sclerosis, and pathological pain
(Abraham, 2001; Teismann et al., 2003; Barbeito et al., 2004; Swanson et al., 2004;
Teismann and Schulz, 2004; Wieseler-Frank et al., 2004).
Reactive gliosis refers to cellular changes that astrocytes undergo following brain
trauma. Astrocytes are the most abundant cell population in the brain, and they have
many supportive functions for neurons. Activation of astrocytes is characterized by an
increase in the size of the cell body and processes and an increase in the levels of an
intermediate filament protein called GFAP (glial fibrillary acidic protein). The most
important questions are what role gliosis plays in brain trauma and neurodegeneration
and whether this process is protective or harmful to the recovery process. There is
evidence to suggest that gliosis is both neuroprotective and harmful. Astrocytes have
neuroprotective properties in the absence of trauma, and these properties are especially
important upon neuronal injury. After acute neuronal damage to the central nervous
system, there is a release of glutamate from neurons (Swanson et al., 2004). Glutamate
and potassium uptake by astrocytes prevents toxic elevations of these molecules in the
brain and extracellular space (Aschner and Kimelberg, 1991; Anderson and Swanson,
2000). Neurodegeneration is also associated with a high level of oxidative stress (Sano et
al., 1997; Marcus et al., 1998). Astrocytes contain the highest concentration of
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antioxidants and protect neurons from oxidative stress (Dringen, 2000; Dringen and
Gutterer, 2002). During both normal brain function and trauma, astrocytes play a vital
role in scavenging potentially toxic agents from the extracellular matrix.
Studies from in vivo mouse models that disrupt the intermediate filament proteins
reveal that gliosis may inhibit recovery after brain trauma. GFAP' mice still exhibit a
normal gliotic response to stab wound or scrapie infection (Gomi et al., 1995; Pekny et
al., 1995). This is most likely due to the redundancy with another intermediate filament,
vimentin (VIM). Mice deficient for both GFAP and Vim exhibit a defect in post-traumatic
glial scarring and a slower healing process (Pekny et al., 1999). These mice also have
remarkable synaptic regeneration relative to wildtype controls (Ishikawa et al., 1997;
Koyama et al., 1999), and astrocytes isolated from these mice are a better substrate for
outgrowth of neurites in vitro (Menet et al., 2000). Cell proliferation, cell survival, and
neurogenesis in the hippocampus of old GFAP-; Vim-/ mice increased 30% compared to
wildtype controls (Larsson et al., 2004). This suggests that age-related gliosis may
restrict neurogenesis in old individuals and that blocking gliosis in this setting has many
potential benefits.
Gliosis may exacerbate the pathologies of individuals with neurodegenerative
disease and may impede neural repair. There is evidence to suggest that inhibiting gliosis
in mice with neurodegeneration disorders or ischemia improves the pathology of these
mice. Anti-inflammatory drugs such as ibuprofen have been shown to suppress the gliotic
response in vivo in a mouse model for Alzheimer's disease and ischemia. Transgenic
mice overexpressing the amyloid precursor protein undergo many of the same
pathological changes as individuals with Alzheimer's disease (Sturchler-Pierrat et al.,
1997). When these mice are administered ibuprofen, the amyloid plaque formation is
greatly reduced, and the gliotic response is blocked (Lim et al., 2000; Jantzen et al.,
2002; Yan et al., 2003). Similarly, dispensing ibuprofen to mice or rats subjected to
ischemia reduces neuronal injury and improves cerebral blood flow and neurological
outcome (Kuhn et al., 1986; Cole et al., 1993; Patel et al., 1993; Antezana et al., 2003).
These studies suggest that blocking the gliotic response in individuals with
neurodegeneration may be a successful therapeutic option.
It is clear that gliosis is involved in neurodegenerative disorders and brain trauma.
However, the molecular mechanisms underlying this process are poorly understood.
There is recent evidence to suggest that activation of the epidermal growth factor receptor
(EGFR) signaling pathway triggers astrocyte activation and reactive gliosis. In the
developing central nervous system, the EGFR regulates astrocyte migration and
differentiation of neural precursor cells into astrocytes (Miettinen et al., 1995; Sibilia and
Wagner, 1995; Kornblum et al., 1998). This pathway is reactivated during
neurodegeneration, ischemia, and tumorigenesis (Birecree et al., 1988; Planas et al.,
1998; Jin et al., 2002; Hayashi et al., 2004). EGFR regulates genes related to reactive
astrocytes and neural disorders. These genes include those involved in extracellular
matrix organization, cell migration, and cytokine production (Liu and Neufeld, 2004). In
response to EGFR, astrocytes produce transforming grown factor 3, brain-derived
neurotrophic factor, fibroblast growth factor 2, and nerve growth factor 13, which may all
be beneficial to the survival of neurons (Liu et al., 2006). However, activation of EGFR
generates chondroitin sulfate proteoglycans and laminin, both of which interfere with
axon regeneration after neural injury (McKerracher et al., 1996; Anderson et al., 1998;
Koprivica et al., 2005). One theory is that neural injury induced by neurodegenerative
diseases, tumorigenesis, and ischemia initiates inappropriate activation of a EFFR-driven
developmental program (Liu et al., 2006). This model explains the duality of gliosis and
suggests that this early developmental program is harmful to neurons in adult individuals.
Most of the research done on gliosis concludes that this process does more harm
than good. For this reason, it is not surprising that many therapeutic options for
neurodegenerative diseases and ischemia involve inhibition of gliosis. A better
understanding of the molecular and cellular mechanisms that contribute to gliosis will
lead to more effective and targeted therapies for these diseases.
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ABSTRACT
Bmil is a Polycomb Group protein that functions as a component of Polycomb
Repressive Complex 1 (PRC 1) to control axial skeleton development through Hox gene
repression. Bmil also represses transcription of the Ink4a-Arflocus and is consequently
required to maintain the proliferative and self-renewal properties of hematopoietic and
neural stem cells. Previously, one E2F family member, E2F6, has been shown to interact
with Bmil and other known PRC1 components. However, the biological relevance of this
interaction is unknown. In this study, we use mouse models to investigate the interplay
between E2F6 and Bmil. This analysis shows that E2f6 and Bmil cooperate in the
regulation of Hox genes, and consequently axial skeleton development, but not in the
repression of the Ink4a-Arflocus. These findings underscore the significance of the
E2F6-Bmil interaction in vivo and suggest that the Hox and Ink4a-Arfloci are regulated
by somewhat different mechanisms.
INTRODUCTION
The E2F transcription factors are a family of key regulators of cell proliferation
and differentiation (Dyson, 1998; Nevins, 1998; Trimarchi and Lees, 2002). They act by
controlling the transcription of genes whose expression is essential for cell cycle
progression and DNA synthesis. In mammals, eight E2f genes (E2fl-8) have been
identified. E2fl-5 encode proteins that function as transcriptional activators or repressors
by virtue of their association with the family of pocket proteins, pRB, p107, and p130.
E2f6-8 are more distantly related members of the E2F family. In particular, they lack the
domain required for pocket protein-binding and are therefore not susceptible to pocket
protein regulation (Cartwright et al., 1998; de Bruin et al., 2003; Gaubatz et al., 1998;
Logan et al., 2004; Maiti et al., 2005; Morkel et al., 1997; Trimarchi et al., 1998;
Trimarchi et al., 2001). E2F6 binds DNA as a heterodimer with DP, in a similar manner
to E2F1-5, but due to the absence of a transactivation domain it does not activate
transcription (Cartwright et al., 1998; Gaubatz et al., 1998; Morkel et al., 1997;
Trimarchi et al., 1998;). Early studies showed that over-expressed E2F6 can repress
classic E2F-responsive genes, at least in part, by binding to E2F-responsive promoters
and blocking access to other activating E2Fs (Gaubatz et al., 1998; Morkel et al., 1997;
Trimarchi et al., 1998). Subsequently, E2F6 was shown to exist in complexes that contain
both chromatin remodeling enzymes and members of the mammalian Polycomb Group
(PcG), including Bmil, Ringl, and RYBP (Attwooll et al., 2004; Ogawa et al., 2002;
Trimarchi et al., 2001). The PcG proteins, first identified in Drosophila, form large
multimeric complexes that are responsible for the repression of the Hox genes, which
determine the patterning of the developing embryo (Kennison 1995; Simon, 1995). The
documented interaction between E2F6 and PcG proteins suggested that E2F6 might
actively enforce repression of E2F target genes in vivo through recruitment of the PcG
complex(es) and might also participate in the regulation of known PcG-responsive
targets.
In mammals, there are at least two distinct PcG complexes, called Polycomb
Repressive Complexes (Otte and Kwaks, 2003). The Eed-containing PcG complex,
PRC2, initiates polycomb-mediated repression, whereas the Bmi-1-containing PcG
complex, PRC 1, maintains the repression at later stages of development. Loss of proteins
of the PcG-PRC2 in mice generally results in early embryonic lethality (Faust et al.,
1995; O'Carroll et al., 2001) whereas PcG-PRC1 mutant mice typically survive until
birth and display homeotic transformations of the axial skeleton (Akasaka et al., 1996;
Akasaka et al., 1997; del Mar Lorente et al., 2000; van der Lugt et al., 1994). Notably,
E2F6 has been shown to interact with known components of both PcG-PRC I1 and PcG-
PRC2 (Attwooll et al., 2004; Ogawa et al., 2002; Trimarchi et al., 2001). Based on our
previous association data (Trimarchi et al., 2001), we have focused our attention on
understanding the interplay between E2F6 and Bmil.
Bmil-deficient mice display defects in axial skeletal patterning, hematopoiesis,
the central nervous system, and the peripheral nervous system (Jacobs and van Lohuizen,
2002; van der Lugt et al., 1994). In the hematopoietic system, the stem cell defect results
in a loss of mature T and B cells, hypocellularity of the bone marrow, decreased spleen
size, and an involuted thymus (Lessard and Sauvageau, 2003; van der Lugt et al., 1994).
The neurological defects in the Bmil mutant mice include an ataxic gait, seizures,
hypocellularity of the molecular and granular layers of the cerebellum, and astrogliosis in
the cortex and cerebellum of the brain (Leung et al., 2004; Molofsky et al., 2003; van der
Lugt et al., 1994; Zencak et al., 2005). The neurological and hematopoietic defects can
be partially attributed to a deficiency in the proliferation and self-renewal capacity of the
stem cells in these compartments (Lessard and Sauvageau, 2003; Molofsky et al., 2005;
Park et al., 2003; Zencak et al., 2005).
The proliferation defects observed in vivo are consistent with a role for the PcG
proteins in the control of the cell cycle. Indeed, mouse embryonic fibroblasts (MEFs)
deficient for Bmil, Mel-18or M33 have impaired proliferation properties and undergo
premature senescence (Core et al., 1997; Jacobs et al., 1999). The cell cycle defects in the
Bmil-' MEFs result from the derepression of the Ink4a-Arf locus (Jacobs et al., 1999).
This locus encodes two proteins, p1 6INK4a and p1 9A F, which regulate cellular proliferation
and apoptosis. Only a few PcG proteins have been reported to bind DNA directly
including Mel-18 and YY1 (Brown et al., 1998; Kanno et al., 1995). These proteins
cannot account for all the Polycomb DNA binding activity suggesting that other DNA
binding factors may facilitate the recruitment of PcG complexes to specific promoters.
Notably, several E2F family members have been shown to play a direct role in the
transcriptional regulation of p1 9 API (Aslanian et al., 2004). Because E2F6 associates with
PcG proteins and is able to directly bind DNA in a sequence-specific manner, we
hypothesized that E2F6 might act to recruit PcG complexes to target promoters including
Arf. To investigate the role of E2F6 in development and cell cycle control, we and others
have generated E2f6-deficient mice (this study; Storre et al. 2002). Consistent with our
prior observation that E2F6 interacts with Bmil and other PRC1 components (Trimarchi
et al., 2001), E2f6' mice display subtle axial skeletal transformations. It is well
established that the combined mutation of two PcG-PRC1 components in flies or mice
yields synergistic phenotypic effects (Adler et al., 1991; Akasaka et al., 2001; Bel et al.,
1998; Kwon et al., 2003). Thus, to test for a possible genetic interaction between E2F6
and Bmi 1, we have generated mice and MEFs that are deficient for both E2f6 and Bmil
genes. Our data show that E2f6-deficiency increases the severity of the axial skeletal
defect in Bmil mutant mice but does not modulate the other Bmil mutant phenotypes.
RESULTS
E2f6 mutant mice are viable but display axial skeletal defects.
In order to study the role of E2F6 in vivo, we generated an E2f6 mutant mouse
strain in which we have deleted a large proportion of the E2f6 coding sequences
including the exons that encode the DNA binding, leucine zipper and marked box
domains (Figure lA). Western blotting of E2f6' MEFs confirms loss of the E2F6 protein
(Figure IB). Consistent with previous studies (Storre et al., 2002) we find that E2f6-
deficient mice are born at the expected frequency (120% of expected, n=233) and display
no gross morphological defects. Previous studies have not assessed the lifespan in
littermates. We generated a cohort of aging animals and found that there was no
difference in the percentage of E2f6'i', E2f6"' versus E2f6' mice that were alive after
530 days (70%, 68% and 75%, respectively; Figure IC) or in the eventual cause of death
of these animals. Thus, we conclude that E2f6-loss has no detectable effect on murine
viability.
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Figure 1: E2f6 mutant mice are fully viable and display axial skeletal
transformations.
(A) Generation of the E2f6' mice. The E2f6 genomic locus comprises 8 exons that
include noncoding sequences (black boxes) coding sequences (gray boxes) and an
alternatively spliced exon 2 (white box). DBD, DNA binding domain; DIM, dimerization
domain; MB, marked box domain. The E2F6 mutant allele was generated by replacing
coding sequences of exons 4 through 8 with a PGK-neo cassette that includes a STOP
codon at the beginning. PGK-neo, neomycin resistance gene under the regulation of the
PGK promoter for positive selection. Disruption of the E2f6 locus was confirmed by (B)
Western of lysate from Wildtype and E2f6' MEFs. (C) Survival curve of E2f6 wildtype,
heterozygote and mutant mice followed for over 500 days. (D) Ventral view of axial
skeletons of newborn E2f'' and E2f6' mice stained with alcian blue (cartilage) and
alzarin red (bone). E2f6' mice display two axial skeletal transformations, the thirteenth
thoracic vertebra (T13) is transformed into the first lumbar vertebra (Ll) as shown by the
degeneration of the thirteenth ribs and the sixth lumbar vertebra (L6) is transformed into
the first sacral vertebra (S 1) as evidenced by the formation of the sacral-iliac joints.
-TI^
-LI--
-SIi
5+/+ E2f6"E2ft
We have previously shown that E2F6 associates with Bmil and other components
of the PcG-PRC1 complex in vivo. Because loss of Bmil in mice results in posterior
transformations along the entire axial skeleton (van der Lugt et al., 1994), we analyzed
the skeletons of E2f6'i', E2f6"' and E2f6A mice at postnatal day 3 (P3) by staining with
Alcian blue and Alzarin red, which stain the cartilage in blue and the bone in red (Figure
ID). Similar to Bmil and other PcG knockout mice (Akasaka et al., 1996; van der Lugt et
al., 1994), E2f6 mutant mice displayed posterior transformations. First, the thoracic
vertebra T13 is transformed into a lumbar vertebra L1 as evidenced by the lack of ribs in
0% of E2f6' +, 9% of E2f6"', and 67% of E2f6' animals. Second, the lumbar vertebra L6
is transformed into the sacral vertebra S1 as shown by its association with the iliac bones
in 0% of E2f6+'i , 35% of E2f6"', and 80% of E2f6/ mice (Figure lD). These
observations are consistent with those of Storre et al. (2002) who previously reported T13
to L1 and L6 to S1 transformations in a distinct E2f6 mutant mouse model. Together, our
data suggest that E2f6 mutation results in dosage-dependent posterior transformations of
the axial skeleton that are reminiscent of axial skeletal transformations seen in Bmil and
other PcG-PRC1 knockout mice.
Viability of E2f6';Bmil " mice.
Compound mutants of PcG-PRCl proteins have been generated in flies and mice
resulting in dramatic synergistic effects (Adler et al., 1991; Akasaka et al., 2001; Bel et
al., 1998; Kwon et al., 2003). Thus, to determine the biological relevance of the
interaction between E2F6 and Bmil, we have generated and analyzed E2f6';Bmil /
mice. E2f6 deletion alone does not affect the viability and survival of mice. In contrast,
while Bmil' - mice are born at the expected frequency, they are selectively cannibalized
by their mothers shortly after birth and only approximately 50% survive into adulthood
(van der Lugt et al., 1994). These animals are significantly smaller than their wildtype
littermates and display poor health that results in early lethality (3 to 20 weeks). In good
agreement with this prior analysis, examination of the progeny from E2f6+';Bmi lJ'
intercrosses showed that Bmil -' single mutant mice were underrepresented at 3 weeks of
age (51% of expected: Table 1) but were present at near expected frequencies at
embryonic day 18.5 (122% of expected: Table 2). In contrast, E2f6A;Bmil /' mice arising
Table 1: Viability of E2f6;Bmil compound mutant mice at three weeks of age.
n=250 E2f6÷* E2f6÷' E2f6*" E2f6" -
Bmil' /÷  Bmil -' Bmil"-  Bmil -
Expected 15.63 15.63 31.25 15.63
Observed 16 8 24 6
% of expected 102 51 77 38
*Mice generated from E2f6`':Bmil1' intercrosses and genotyped at three weeks of age.
Table 2: Viability of E2f6:Bmil compound mutant mice at E18.5.
n=105 E2f6÷+  E2f6~' E2f6"  E2f6"-
Bmil"P Bmil --  Bmil -" Bmil'-
Expected 6.56 6.65 13.13 6.56
Observed 5 8 7 3
% of expected 76 122 53 46
* Mice generated from E2f6÷':Bmil'÷ intercrosses and genotyped at embryonic day 18.5.
from E2f6+';Bmil' intercrosses seemed to be underrepresented at both three weeks
(38% of expected; Table 1) and also at E18.5 (46% of expected; Table 2). To better
assess the relative viability of E2f6';Bmil'/ versus Bmil-' embryos, we conducted E2f6'
;BmilJ' intercrosses to generate the test genotypes at a much higher frequency. Analysis
of the resulting progeny showed that there was no significant difference in the viability of
E2f67;Bmil -' versus Bmil -J embryos at E18.5. (Table 3; p=0.87). Therefore, loss of E2F6
has no effect on the viability of Bmil mutant mice. In addition, the E2f6-';Bmi mice
showed a similar degree of growth retardation as their BmilT/ littermates and these two
genotypes both developed severe anemia and had to be sacrificed in a similar time
window (data not shown).
Table 3: Viability of E2f6:Bmil compound mutant mice at E18.5.
n=27 E2f6-"  E2f6"' E2f64"
Bmil' •  Bmil' -  Bmil -
Expected 6.75 13.6 6.75
Observed 6 13 8
% of expected 89 96 118
* Mice generated from E2f6' :Bmi l ÷ intercrosses and genotyped at embryonic day 18.5.
E2F6 does not cooperate with Bmil in the regulation of the INK4a-ARF locus.
To determine whether E2F6 and Bmil play cooperating roles, we conducted a
careful analysis of the cells and tissues that are known to be affected by Bmil-loss. The
lethal anemia of Bmil - mice results from a progressive decrease in the number of
hematopoietic cells (van der Lugt et al., 1994). Thus, we first compared the levels of
various hematopoietic lineages in wildtype, E2/f6/ , Bmil' and E2f6I;Bmil- mice at
eight weeks of age. The mutation of E2f6 alone had no detectable effect on the levels of
hematopoietic cells or the distribution of the various white blood cell lineages (Figure 2).
In contrast, the Bmil-' and E2f6'-;Bmil'- mice both showed a profound hematopoietic
defect. First, we observed a significant reduction in the level of hematopoietic cells in the
bone marrow, spleen, and thymus (Figure 2A). Second, there was a clear shift in the
distribution of immature versus mature cells in various lineages. For example, in the
thymus, there was a significant depletion of double positive (CD4+/CD8+) thymocytes,
whereas immature (CD4-/IL2-R+, CD8-/IL2-R+, and CD4-/CD8-) and mature
(CD4+/CD8- and CD4-/CD8+) cells are still present (Figure 2B). Moreover, in the bone
marrow there was a significant shift in the distribution of myeloid (GR+/Mac-1+) versus
B lymphoid cells in both the Bmil ~" and E2f6';Bmil 1' mice. In each case, this leads to a
higher percentage of myeloid cells, although the absolute number of myeloid cells is still
reduced relative to wildtype (Figure 2C). Within the B cell population, we also observed
a greater deletion of the immature B cells (B220+/HSA+; seven fold decrease in the
percentage of cells) than the mature B cells (B220+/IgM+; three fold decrease in the
percentage of cells) when compared with wildtype (Figure 2C). Similar results were seen
in the spleen (data not shown). These changes are all consistent with the known defect in
the maintenance and self-renewal capacity of the BmilJ' hematopoietic stem cells.
Importantly, there was no significant difference in the degree of these defects in the E2f6
';Bmil-' versus the Bmil 1' mice, indicating that E2F6-loss does not modulate the effect of
Bmil-deficiency on the hematopoietic compartment.
Bmil deficient mice exhibit hypocellularity of various layers of the cerebellum
and develop ataxia at the age of 2-4 weeks (Leung et al., 2004; van der Lugt et al., 1994).
Thus, we tested whether the loss of E2F6 modulates these neuronal defects. First, we
screened animals from E2f6÷';Bmil'÷ intercrosses that survived to 2 months of age for
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Figure 2: E2F6-loss does not modulate the hematopoietic defect within Bmil mutant
mice.
(A) Cell counts of single cell preparations made from the bone marrow, spleen, and
thymus of eight week old mice. E2f6+'+;Bmi l +l' n=2; E2f6';Bmil +]' n=2; E2f6+' +;Bmi lJ
n=3; E2f6' -;Bmi l - - n=l; E2f6';Bmil -' n=3. FACS analysis of single cell preparations
made from the thymus (B) and bone marrow (C) and immunostained with the indicated
antibodies. Results are presented as percentage of cells. E2f6+'+;Bmil+'+ n=2; E2f61-
;Bmil'+/ n=2 for part B, n=3 for part C; E2f6+'';Bmil n=3; E2f6+';Bmil/ n=1 for part
B, n=2 for part C; E2f6';Bmil- n=3.
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ataxia (data not shown). This defect was completely absent in animals that were either
wildtype or Bmil'+ , irrespective of their E2f6 status. In contrast, we observed ataxia in a
similarly high proportion of the Bmil' (60%; n=4), E2f6"';Bmil - (65%; n=13) and
E2f6';Bmil /' (70%; n=7). We did observe a general correlation between the degree of
growth retardation and the likelihood that an animal would develop ataxia. It is unclear
whether these defects are causally linked or whether they simply reflect some variation in
the penetrance of Bmil mutation in the mixed (C57/BL6 x 129S/v) genetic background of
our animals. However, our data clearly show that E2f6 status did not alter either the
penetrance or the time of onset of the ataxia. To complement this analysis, we also
performed a histological analysis of brain sections of single and double mutant animals
(Figure 3). Consistent with previous results, the Bmil' cerebellums were significantly
smaller than wildtype with all three layers of the cerebellum affected. We observed a
similar level of cerebellum hypocellularity in the E2f6-' ;Bmil' mice. Given these
observations, we conclude that E2F6-loss does not modulate either the defective
cerebellar development or the consequent ataxia of the Bmil-deficient mice.
It is well established that Bmil-loss leads to the derepression of the Ink4-Arf locus
and the resulting upregulation of p 161NK4a and pl9ARF .This upregulation is a key
determinant of the hematopoietic and neural defects of the Bmil' mice via impairment of
the self-renewal capacity of hematopoietic and neural stem cells (lessard and Sauvageau,
2003; Molofsky et al., 2005; Molofsky et al., 2003; Park et al., 2003; Zencak et al.,
2005). The Ink4-Arfderepression was first observed, and is best characterized, in Bmil/
MEFs where it causes impaired proliferation and premature senescence (Jacobs et al.,
1999). Given this fact, and the documented role of other E2F family members in the
Figure 3
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Figure 3: E2f6-;Bmil"' and Bmil'" mice display defects in gross cerebellar structure.
Hematoxylin and eosin staining of cerebellum sections from the midline of 8 week old
wildtype, Bmil mutant, and E2f6;Bmil compound mutant mice.
regulation of Arf in MEFs (Aslanian et al., 2004), we also compared the properties of
wildtype, Bmil', E2f6' and E2f6';Bmil' MEFs. E2f6/ MEFs displayed no obvious
proliferation defects (data not shown). In contrast, Bmil- MEFs showed a defect in
asynchronous proliferation (Figure 4A) and underwent premature senescence (Figure 4B)
as previously reported (Jacobs et al., 1999). In addition, we found that serum deprived
Bmil / MEFs were impaired in their ability to re-enter the cell cycle following the re-
addition of serum (Figure 4C). There was some variation in the degree of these defects
from one cell line to the next, likely because of the mixed genetic background. We also
derived five E2f6'- ;Bmil' MEF lines from four different litters and compared their
properties with those of MEFs derived from Bmil-' (n=5) and wildtype (n=4) littermates.
The presented data are from cell lines derived from one representative litter (Figure 4).
The E2f6';Bmil' MEFs showed defects in asynchronous proliferation, cellular
senescence and cell cycle re-entry that were comparable to those of the Bmi 1-' MEFs
(Figure 4A-C). Consistent with this finding, real-time PCR analysis of RNA collected
from these MEFs revealed the E2F6 status did not change the level of derepression of
p 161NK4 a and pl 9ARF in the Bmil'/ MEFs (Figure 4D). Similarly, the levels of two E2F6
repressed genes, STAG3 and SMC1B, were not further derepressed in compound mutant
MEFs (data not shown). These results suggest that E2F6 does not play a role in
repression of INK4a-ARF.
Bmil and E2F6 synergize in axial skeleton development and co-regulate Hox genes.
To determine whether E2f6 and Bmil synergize in axial skeletal development, we
examined the axial skeletons of all genotypes arising from a double heterozygous cross.
Figure 4
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Figure 4: Cell cycle properties of E2f6 and Bmil mutant MEFs.
Mouse embryonic fibroblasts of wildtype (*), Bmil mutant (A, X), and E2f6;Bmil
compound mutant (*, 0) mice were assayed for (A) asynchronous proliferation rate, (B)
senescence properties, (C) S-phase re-entry following serum withdrawal and re-addition,
and (D) p16INK 4a and p 1 9ARF expression by RT-PCR from serum-starved cells.
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Since 50% of the Bmil' mice die perinatally, we conducted this analysis using E18.5
embryos to ensure good representation of Bmil" and E2f6/- ;Bmil' animals (Figure 5).
Bmil-'mice are known to display morphological abnormalities along the anteroposterior
axis that indicate posterior transformations of vertebra identity (van der Lugt et al.,
1994). These include (1) an extra piece of bone rostral to the cervical vertebra CI; (2) a
Cl to C2 conversion; (3) a partial C7 to T1 (thoracic vertebra) conversion evidenced by
the presence of ribs at C7, which then fuse on the ventral side with the ribs associated
with T (in some cases, the transformation was full, that is, the C7 rib connected to the
sternum instead of fusing with the T1 rib); (4) a T7 to T8 conversion resulting in only six
instead of seven vertebrosternal ribs; (5) a T13 to L1 (lumbar vertebra) conversion shown
by the absence of ribs at T13; and (6) an L6 to S1 (sacral vertebra) conversion evidenced
by the joints between L6 and the iliac bones. Consistent with prior studies, we observed
all of these transformations in the Bmil' embryos with partial penetrance (Figure 5).
Analysis of the compound mutants showed that E2f6 mutation increased the severity of
the Bmil -' skeletal defects in a dose dependent manner (Figure 5B). Specifically, deletion
of only one allele of E2F6 was sufficient to increase the penetrance of the C to C2, C5
to C6, partial C7 to T1, T13 to L1, and L6 to S transformations. Further deletion of the
remaining E2f6 allele led to an even higher penetrance, indicating that E2F6 and Bmil
synergistically contribute to these abnormalities. No synergy was found for the extra, C7
to T1 (full), and T7 to T8 transformations, suggesting that these defects are specific to
Bmil-loss. However, in the case of the extra piece of bone (E) we observed an increase in
the E2f6~';B mil- but not in the E2f6i;Bmil' mice. As this piece of bone is very small
and weakly attached, we cannot rule out the possibility that it was broken off during
Figure 5
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Figure 5: E2f6 and Bmil show a genetic interaction in the development of the axial
skeleton.
(A) Alcian blue (cartilage) and alzarin red (bone) stainings of wildtype, Bmil mutant and
E2f6;Bmil compound mutant mice at E18.5. The following skeletal transformations are
depicted in the Bmil and E2f6:Bmil compound mutant mice: An extra piece of bone
anterior to the first cervical vertebra (Cl); the Cl vertebra is transformed into the second
cervical vertebra (C2) as evidenced by the altered morphology; the seventh cervical
vertebra (C7) is transformed into the first thoracic vertebra (T1) as shown by the presence
of vertebrosternal ribs. The right panel shows the novel C5 to C6 transformation present
in the E2f6 mutant and E2f6;Bmil compound mutant mice. This is evidenced by the
presence of a piece of cartilage on C5 instead of on C6. (B) Penetrance of axial skeletal
transformations in E2f6;Bmil compound mutant embryos.
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manipulation of the axial skeletons. Finally, we have identified a novel transformation,
the C5 to C6 conversion that occurs in 10% of E2jf6- embryos and 23% of E2f6';Bmil'-
embryos but was never detected in the Bmil /' embryos. The increase in penetrance of
some, but not all, posterior transformations in the E2f6';Bmil - embryos underscores the
conclusion that E2F6 influences the regulation of a subset of Bmil target genes.
It is well established the axial skeletal defects in the Bmil mutants results from
the derepression of Hox genes that are essential for embryonic patterning. The observed
synergy between E2f6 and Bmil in axial skeletal development suggests that E2F6 and
Bmil might co-regulate Hox genes. To address this question, we first used real-time PCR
analysis to compare Hox mRNA levels genes in the wildtype (n=2), Bmi-' (n=2), and
E2f6;Bmil DKO (n=3) MEFs used above to assess Ink4a-Arf expression. Although
E2F6-loss had no effect on the level of derepression of p161NK4 a and pl9AR in the Bmil-
MEFs (Figure 4D), it did modulate the Bmil mutant phenotype with regard to the Hox
genes (Figure 6A). The Bmil-' MEFs had increased mRNA levels of HoxCIO (both lines
analyzed), HoxA9 (both lines analyzed) and HoxB6 (1 out of 2 lines analyzed). Loss of
E2F6 in the Bmil mutant cells led to further deregulation of HoxB6 and HoxClO, but not
HoxA9, in every E2f6;Bmil mutant cell line analyzed (Figure 6A and data not shown).
The mRNA levels of HoxB6, HoxClO, or HoxA9 were unaffected by the mutation of E2f6
alone (data not shown) indicating that this reflects a synergistic effect of E2f6 and Bmil
in Hox gene regulation.
The MEF analysis supports our genetic evidence that E2f6 and Bmil act together
to regulate Hox genes but not Arf. However, these experiments do not establish whether
E2F6 is directly, or indirectly, involved in the transcriptional regulation of the Hox genes.
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Figure 6: E2f6 and Bmil co-regulate Hox genes.
(A) Real-time PCR analysis of Hox genes in MEFs. (B) Chromatin immunoprecipitation
analysis of mouse embryonic stem cells. Sonicated, cross-linked chromatin was
immunoprecipitated with a Bmil, E2F6, or control IgG antibody and the purified DNA
was analyzed by PCR with primers specific for the promoter of HoxA7, HoxAlO,
HoxAll, Arf, or a control sequence (1kb upstream of the E2F1 promoter).
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To address this question, we wished to evaluate the promoter occupancy of the Hox
genes. It has previously been shown that repression of Hox genes and other key
developmental regulators is established in embryonic stem (ES) cells (Boyer et al., 2006).
Thus, we used murine ES cells to perform chromatin immunoprecipitation on four genes,
HoxA7, HoxAlO, HoxAll, and Arf, which have previously been shown to be directly
regulated by Bmil (Bracken et al., 2007; Cao et al., 2005; Kotake et al., 2007; Xi et al.,
2007). We found that Bmil was directly bound to the promoters of HoxA7, HoxA10,
HoxAll, and Arf in mouse embryonic stem cells (Figure 6B). In contrast, E2F6 bound
specifically to the promoters of HoxAlO and HoxAll, but did not associate with either
HoxA7 or Arf (Figure 6B). These results provide in vivo biochemical evidence of the co-
regulation of a subset of Hox genes by E2F6 and Bmil and reinforce the conclusion that
E2F6 is not required for repression of Arf.
DISCUSSION
Bmil is a key component of the PRC1 repressor complex. Bmil mutant mice have
axial skeletal transformations that reflect a key role for Bmil in the appropriate
repression of the Hox genes (Akasaka et al., 1996; Akasaka et al., 1997; del Mar Lorente
et al., 2000; van der Lugt et al., 1994). Additionally, Bmil-deficient mice have impaired
proliferation and premature senescence due to the upregulation of Ink4a-Arf (Jacobs et
al., 1999). Bmil loss and upregulation of p1 6INK4a and pl 9 ARF compromises the
proliferative and self-renewal capacity of stem cells in the developing mouse (Lessard
and Sauvageau, 2003; Molofsky et al., 2003; Park et al., 2003). This causes impaired
development of both the hematopoietic compartment and nervous system of Bmil mutant
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mice. Consequently, these mice display reduced newborn survival, ataxia, anemia, and a
reduction of cell populations in the hematopoietic compartment (van der Lugt et al.,
1994). The neural stem cell defect can be partially rescued by disruption of the Ink4a-Arf
locus (Molofsky et al., 2005). Although Bmil has been shown by chromatin
immunoprecipitation to be present at the promoters of p16INK 4a and p 9 ARF (Bracken et al.,
2007; Kotake et al., 2007), Bmil is unable to directly bind to DNA in a sequence-specific
manner (Alkema et al., 1997; Tagawa et al., 1990).
We have previously established that E2F6 associates with Bmil and other known
components of the PRC1 complex in vivo (Trimarchi et al., 2001). Since other members
of the E2F family are known to regulate Arf, we hypothesized that E2F6 might cooperate
with Bmil in the regulation of the Ink4a-Arflocus, and perhaps also in axial skeletal
development. To address this question, we have generated E2f6 mutant mice and
subsequently E2f6;Bmil compound mutants. Despite the documented role of various E2F
family members in the regulation of Arf(Aslanian et al., 2004), we did not detect any
evidence that E2F6 contributes to the regulation of the Ink4a-Arf locus. First, E2F6-loss
had no detectable effect on the proliferation properties of MEFs and there was no
detectable derepression of p 9ARF . Second, we observed no further derepression of
p16INK4 a and pl9ARF in E2f6¾;Bmil' versus Bmil /i MEFs and no significant difference in
the proliferative or senescent properties of these two genotypes. Finally, E2F6 was not
detected at the promoter of Arf in ES cells. We did find that Bmil deficient cells have a
cell cycle re-entry defect that has not been previously reported. However, the compound
mutant cells do not differ significantly in their ability to re-enter the cell cycle.
Previously, E2F4 had been shown to compensate for loss of E2F6 at the promoters of cell
cycle genes (Zhu et al., 2004), and one hypothesis was that a lack of a genetic interaction
between E2F6 and Bmi 1 could be due to E2F4 or another E2F family member
compensating for the loss of E2F6 at Arf. However, the promoter occupancy analysis
presented here strongly suggests that E2F6 plays little or no role in the direct regulation
of Ink4a-Arf. Certainly, our data show that E2F6 is fully dispensable for the appropriate
regulation of this locus. Consistent with this finding, the loss of E2F6 did not exacerbate
the defects in either the hematopoietic compartment or the cerebellar development of the
Bmi 1 mutant mice that largely result from the derepression of Ink4a-Arf. Thus, these
data suggest that E2F6 does not influence the regulation of Ink4a-Arfby Bmi 1 by either
direct or indirect mechanisms.
In stark contrast to the regulation of Ink4a-Arf, our data show a role for E2f6 in
axial skeletal development. First, data from both this and previous (Storre et al., 2002)
studies show that, like other PcG proteins, E2F6-loss results in axial skeletal
transformations. Second, we find that E2f6 mutation acts in a dosage-dependent manner
to increase the penetrance of skeletal transformations in the Bmil deficient background.
This genetic analysis suggests that E2F6 plays a vital role in the regulation of a subset of
Bmi 1 target genes, presumably the Hox genes. To further this study, we took a more
biochemical approach to analyze if the increased penetrance of the skeletal
transformations in the E2f6;Bmil mutant mice is due to enhanced deregulation and loss
of direct transcriptional control of the Hox genes. Indeed, we did find enhanced
deregulation of a subset of Bmi 1 target Hox genes and a direct association of E2F6 with a
subset of Bmil-responsive Hox gene promoters. This biochemical analysis clearly
provides insight into how E2F6 loss in Bmil mutant mice leads to an increase in the
penetrance of skeletal transformations. Furthermore, it underscores the diversity of the
Bmil complexes and the mechanisms by which it regulates target genes. Finally, we have
established that E2F6 directly regulates Hox genes in vivo and have reported a novel C5
to C6 transformation which is present in E2f6 and E2f6;Bmil mutant embryos. Thus, we
conclude that E2F6 and Bmil act synergistically in development of the axial skeleton.
Taken together, our data show that E2F6 plays a vital role in the regulation of a subset of
Bmil target Hox genes that govern the anteroposterior patterning of the developing
embryo but is not required for the regulation of Ink4a-Arf and the control of cellular
proliferation.
EXPERIMENTAL PROCEDURES
Generation and genotyping of E2f6' mice
The BAC clone b39J22 (Research Genetics) known to contain the E2f6 genomic
locus was mapped and cloned to obtain the sequences necessary for designing the
targeting strategy. The targeting vector described above was introduced into 129Sv Ji
ES cells by electroporation and the cells were selected with G418 and Gancyclovir.
Ninety-six resistant clones were picked for genotyping. E2f6' cells were detected by
Southern blot using external 5' and 3' probes as well as a neomycin probe. Once the
heterozygous clones were identified and verified to contain a diploid genome by
karyotyping, they were injected into C57/BL6 3.5 d.p.c. blastocysts. The injected
blastocysts were subsequently implanted into pseudo-pregnant females and the chimeric
progeny were identified by coat color. Mice with a high contribution of agouti cells were
mated to pure C57/BL6 mice. The agouti progeny of these mice were genotyped by PCR
of DNA obtained from ear or tail pieces using the common primer 5'-
ATCTCTGTCTGGTCTGATCC-3', the wildtype E2f6-specific primer 5-
GATGCCATCCAAGACATTGG-3', and the mutant targeting vector specific primer 5-
GCCGCATAACTTCGTATAGC-3'. The E2f6÷" mice were then interbred to produce
E2f6' mice.
Histological and skeletal analysis
Euthanized animals were dissected and processed for histological analysis. Soft
tissues were fixed in 10% formalin and hard tissues were fixed in Bouin's fixative.
Paraffin sections were prepared and stained with hematoxylin and eosin. Skeletal
analysis was performed on 3-day old mice and 18.5 d.p.c. embryos. After removing the
skin and viscera, the skeletons were fixed in acetone and stained with cartilage-specific
Alcian Blue and bone-specific Alzarin Red. Soft tissue was cleared with KOH.
Mouse embryonic fibroblasts and cell cycle assays
MEFs were prepared from 13.5 d.p.c. embryos as previously described (Humbert
et al., 2000) and genotyped by PCR of DNA obtained from yolk sacs. Proliferation
curves were obtained by plating 2x104 MEFs in triplicate in 24-well plates. At the
indicated time points, MEFs were trypsinized and counted. For cell cycle re-entry assays,
2x10 5 MEFs were plated in triplicate in 6-well plates. After 2 days of growth in media
containing 10% serum, cells were incubated in media containing 0.1% serum for 3-4
days. Re-entry into the cell cycle was induced by incubation in media containing 10%
serum and at the indicated time points, 5 [Ci of 3H-thymidine was added to the cells for 1
hour. Cells were then scraped from the plates and cell pellets were analyzed for 3H-
thymidine incorporation using a scintillation counter. A 3T3 protocol was followed to
monitor senescence. 3x10 5 MEFs were plated in duplicates in 6-cm plates and re-fed 2
days later. On the third day, they were trypsinized, counted and replated. The fold
replication was determined by dividing the number of cells obtained at day 3 by 3x 105.
Western blots were performed as described previously (Moberg et al., 1996) with 50-100
Rig of whole cell lysates using primary antibodies against E2F6 (mouse monoclonal,
clone 2E10, J.A. Lees) and p 9 ARF (rat monoclonal, sc-32748, Santa Cruz Biotechnology).
Real-Time PCR Analysis
For RT-PCR analysis, RNA was collected from asynchronously proliferating cell
pellets. RNA was processed using the Rneasy MinElute Cleanup Kit (Qiagen, 74204).
cDNA was made from the RNA using SuperScript First-Strand Synthesis System
(Invitrogen, 11904-018). 2pl of cDNA (diluted 1:100), 0.91 M primer pair, and 10Pl of
SybrGreen Master Mix (Applied Biosystems, 4309155) was used for each PCR reaction.
RT-PCR signals were normalized to an ubiquitin internal control. Primer sequences are
available upon request.
Analysis of the hematopoietic compartment
Single-cell preparations were made from the bone marrow, thymus, and spleen of
eight-week old mice by mincing the tissue and then pressing through a nylon mesh. Cells
were then counted with a hemocytometer. For flow cytometry analysis, cells were
resuspended in a 96-well plate at 3x105 cells/well in FACS buffer (PBS, 0.5% BSA,
0.1%NaN 3). Cells were washed with FACS buffer, blocked with Fc Block (1/4000 in
FACS buffer, BD Biosciences), and incubated with saturating amounts of monoclonal
antibodies conjugated to FITC, PE, or Biotin at 40C for 30 minutes in the dark. Cells
were then washed 2 times with FACS buffer and, if required, incubated with a secondary
antibody (Streptavidin-APC) at 40C for 30 minutes in the dark. Cells were then washed 2
times with FACS buffer and resuspended in 400pl PI-containing FACS buffer (lyg/ml).
Cells were then analyzed on a FACScan. The following antibodies were used: Anti-
mouse IgM-Biot (IB4ABI, Southern Biotechnology Associates), PE-Anti-Mouse CD8a
(553032, BD Pharmingen), Biotin Anti-Mouse CD4 (553044, BD Pharmingen), PE Anti-
mouse B220 (553089, BD Pharmingen), PE Anti-mouse Ly-6G (Gr-1) (553128, BD
Pharmingen), Biotin Anti-mouse CD1 lb (Mac-1) (557395, BD Pharmingen),
Streptavidin-APC (554067, BD Pharmingen), FITC Anti-mouse CD28 (IL2-R) (553071,
BD Pharmingen), Biotin Anti-mouse CD24 (HSA) (555296, BD Pharmingen).
Chromatin Immunoprecipitation
Chromatin immunoprecipitation was performed as previously described (Aslanian
et al., 2004). Oligonucleotide primers (Integrated DNA Technologies) used for PCR
analysis are available upon request. Antibodies used were E2f6 (sc-8366, Santa Cruz
Biotechnlogy) and Bmil (Bmil-1, J.A. Lees).
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Chapter 3
E2f6 loss suppresses gliosis after neuronal injury
Laurie Friesenhahn and Jacqueline A. Lees
Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, MA
02139, USA.
ABSTRACT
Astrocyte activation or gliosis occurs in response to neurodegeneration and
neuronal death. Upon CNS insult, astrocytes become activated and form a glial scar
around the damaged area. This process provides neuronal protection by restricting
inflammation and regulating the concentration of molecules in the extracellular
environment. However, gliosis has potentially detrimental effects such as the inhibition
of axonal regeneration or the release of cytotoxic agents that trigger degeneration of
neighboring neurons. The molecular mechanisms required to initiate and sustain a gliotic
response are poorly understood. This analysis describes a novel requirement for E2F6 in
gliosis. Upon neural injury, the gliotic response of E2f6' mice is suppressed. This
phenotype is not due to a modulation of apoptosis or proliferation, suggesting that E2f6
loss uncouples cell damage from gliosis.
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INTRODUCTION
The E2F transcription factors act by controlling the transcription of genes that are
essential for cell cycle progression and DNA synthesis (Dyson, 1998; Nevins, 1998;
Trimarchi and Lees, 2002). In mammals, eight E2f genes (E2fl-8) have been identified.
E2fl-5 encode proteins that function as transcriptional activators or repressors by virtue
of their association with the family of pocket proteins. E2f6-8 are more distantly related
members of the E2F family. In particular, they lack the domain required for pocket
protein-binding, and these E2Fs are not susceptible to pocket protein regulation (Morkel
et al., 1997; Cartwright et al., 1998; Trimarchi et al., 2001; de Bruin et al., 2003; Logan
et al., 2004). E2F6 binds DNA as a heterodimer with DP, in a similar manner to E2F1-5.
Due to the absence of a transactivation domain, it does not activate transcription (Morkel
et al., 1997; Cartwright et al., 1998; Gaubatz et al., 1998; Trimarchi et al., 1998). The
repressive functions of E2F6 are achieved through its interactions with chromatin
modifiers and the polycomb group family of proteins (Trimarchi et al., 2001; Ogawa et
al., 2002; Attwooll et al., 2005). The polycomb group proteins are repressors of
homeobox (Hox) genes, which control the anterior-posterior patterning of the developing
embryo.
In vivo mouse models have revealed novel roles for E2Fs in different
developmental processes. To uncover the roles of E2F6 in development, we and others
have generated mice deficient for this gene (Storre et al., 2002; Courel et al., 2008).
These mice are viable, and they live a normal life-span. In vitro studies did not reveal any
cell cycle or proliferation defects. E2F6 mutant mice, however, exhibit a defect in
spermatocyte development and posterior transformations of the axial skeleton (Storre et
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al., 2002; Courel et al., 2008). The axial skeleton transformations seen in these mice
reflect E2F6's role in Hox gene regulation. In this study, we describe a novel role for
E2F6 in reactive gliosis.
Reactive gliosis refers to cellular changes that astrocytes undergo following brain
trauma. Activation of astrocytes is characterized by an increase in the size of the cell
body and processes and an increase in the levels of an intermediate filament protein
called GFAP (glial fibrillary acidic protein). During both normal brain function and
trauma, astrocytes play a vital role in scavenging potentially toxic agents from the
extracellular matrix. After acute neuronal damage to the central nervous system, there is a
release of glutamate from neurons (Swanson et al., 2004). Glutamate and potassium
uptake by astrocytes prevents toxic elevations of these molecules in the brain and
extracellular space (Aschner and Kimelberg, 1991; Anderson and Swanson, 2000).
Astrocytes also contain the highest concentration of antioxidants and are hypothesized to
protect neurons from oxidative stress following neurodegeneration (Sano et al., 1997;
Marcus et al., 1998; Dringen, 2000; Dringen and Gutterer, 2002). Astrocytes have acute
neuroprotective properties that could potentially relieve stress on neurons after induction
of neurodegeneration or injury to the brain.
There is an increasing amount of evidence that gliosis may exacerbate the
pathologies of individuals with neurodegenerative disease and may impede neural repair.
Inhibiting gliosis in mice with neurodegeneration disorders or ischemia improves the
pathology of these mice. In a mouse model for Alzheimer's disease, anti-inflammatory
drugs such as ibuprofen have been shown to suppress the gliotic response and reduce
amyloid plaque formation (Lim et al., 2000; Jantzen et al., 2002; Yan et al., 2003).
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Similarly, dispensing ibuprofen to mice or rats subjected to ischemia reduces neuronal
injury and improves cerebral blood flow and neurological outcome (Kuhn et al., 1986;
Cole et al., 1993; Patel et al., 1993; Antezana et al., 2003). These studies suggest that
blocking the gliotic response in individuals with neurodegeneration may be a successful
therapeutic option. Little is known about the molecular mechanisms contributing to
gliosis in vivo. There is some suggestion that neural injury induced by neurodegenerative
diseases, tumorigenesis, and ischemia initiates inappropriate activation of a program
required for development of the central nervous system (Liu et al., 2006). This model
explains the duality of gliosis and suggests that this early developmental program is
harmful to neurons in adult individuals.
Our analysis of E2f6 mutant mice did not reveal any defects in the central nervous
system. However, we did find that these mice exhibit a suppression of gliosis when cell
damage is induced with either the injection of a neurotoxin (methylazoxy methanol) or
the loss of Bmil. Bmil loss has been shown to induce apoptosis of cells in the cerebellum
and cortex of mice. Following cell death, Bmil mutant mice demonstrate a gliotic
response. Eight-week old mice deficient for both E2f6 and Bmil fail to undergo gliosis.
To determine whether this defect in gliosis is specific to Bmil loss or whether it occurs
upon the induction of other types of brain injury, we used methylazoxy methanol to
induce brain damage in mice deficient for E2f6. Under these conditions, E2f6 mutant
mice also display a decrease in gliosis. This defect in gliosis was not due to a loss of
proliferation or a reduction of apoptosis. These results suggest that E2F6 plays a vital role
in the induction of gliosis.
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RESULTS
E2f6 loss suppresses gliosis in the cerebellum of eight-week old Bmil mutant mice.
Bmil loss in the cerebellum and cortex induces a gliotic response characterized by
an increase in reactive astrocytes in the molecular layer of the cerebellum and an increase
in GFAP immunoreactivity in activated astrocytes. This response is most pronounced in
the Bergmann's glia in the cerebellum of these mice (Figure 1). As expected, all eight-
week-old wildtype or E2f6 mutant mice analyzed did not exhibit gliosis in the absence of
any brain injury. Gliosis was seen in the cerebellum in five out of seven eight-week-old
Bmil mutant mice. No apoptosis was observed (data not shown), suggesting that the
gliosis seen at this time-point is better characterized as a "glial scar" resulting from
neonatal apoptosis in the cerebellum. In all eight-week-old mice deficient for both E2f6
and Bmil the gliotic response is greatly suppressed (n=5), and this is accompanied by a
reduction in the number of astrocytes seen in the molecular layer of the cerebellum
(Figure 1). These results suggest that E2F6 is required for the gliotic response induced by
the loss of Bmil.
E2f6 loss suppresses gliosis induced by methylazoxy methanol, a neurotoxin.
E2F6 and Bmil interact biochemically (Trimarchi et al., 2001), and participate in
the transcriptional repression of some of the same Hox genes (Courel et al., 2008). For
this reason, it is unclear if the suppression of gliosis seen in mice deficient for both E2f6
and Bmil is due to loss of a repressive complex containing both proteins or if this
suppression is independent of Bmil loss. To test this, we used methylazoxy methanol
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Figure 1
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2X Magnification
20X Magnification
Figure 1: GFAP immunohistochemistry of eight-week-old mice.
GFAP immunohistochemistry marks activated astrocytes and gliosis after brain injury.
(A) Low magnification picture of the cerebellums of eight-week-old wildtype, E2f6
mutant, Bmil mutant, and E2f6;Bmil compound mutant mice. (B) High magnification of
the molecular and granule layer of eight-week-old wildtype, E2f6 mutant, Bmil mutant,
and E2f6;Bmil compound mutant mice. Pronounced GFAP immunoreactivity is seen in
the molecular layer of Bmil mutant mice.
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(MAM), to induce gliosis in mice mutant for only E2f6. MAM, similar to Bmil loss,
inhibits the proliferation of cells in the external granule layer of the cerebellum and
causes apoptosis of these cells. Thus, this drug should recapitulate Bmil loss. MAM was
administered to three-day-old pups obtained from an intercross of E2f6÷' mice. Two days
later, the pups were sacrificed and sectioned for histological analysis. All wildtype pups
(n= 12) exhibited a proper gliotic response. In contrast, gliosis was suppressed in five out
of seven E2f6' mice (Figure 2). Thus, the suppression of gliosis by E2F6 is partially
penetrant and independent of Bmil loss.
The E2F transcription factors are known to control apoptosis and proliferation of
primary cells. Specifically, E2F6 has been shown to modulate the apoptotic response in
human embryonic kidney 293 cells in response to ultraviolet-induced apoptosis (Yang et
al., 2007). However, there was no modification of apoptosis or proliferation in the
cerebellums of wildtype verses E2f6-' pups injected with MAM (Figure 3). In conclusion,
E2f6 loss causes a partially penetrant reduction in gliosis that is not due to a modulation
of apoptosis or proliferation.
E2f6 does not inhibit gliosis in five-day-old Bmil mutant neonates.
In order to better characterize the suppression of gliosis by E2F6, we analyzed
Bmil;E2f6 compound mutant mice at five-days-old. Surprisingly, E2f6 loss did not
suppress gliosis in this setting (n=5; Figure 4). One hypothesis is that there is a threshold
level of gliosis suppressed by E2f6 loss. This hypothesis may also explain the partially
penetrant phenotype observed in the pups injected with MAM.
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Figure 2
Wildtype E2f6-/-
Figure 2: GFAP immunohistochemistry of postnatal day 5 mice injected with MAM.
Postnatal day 3 pups obtained from E2f6+/- intercrosses were injected with methylazoxy
methanol. Two days later, pups were sacrificed and brain tissues were collected.
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Figure 3
Wildtype
TUJNEL, j:: '
Ki67
Figure 3: Analysis of apoptosis and proliferation of MAM injected pups.
Postnatal day 3 pups obtained from E2f6+/- intercrosses were injected with methylazoxy
methanol. Two days later, pups were sacrificed and brain tissues were collected. Tissues
were analyzed by (A) TUNEL staining for apoptosis and (B) Ki67
immunohistochemistry for proliferation.
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Figure 4: GFAP immunohistochemistry of five-day-old mice.
GFAP immunohistochemistry was performed on wildtype, Bmil mutant, and E2f6;Bmil
compound mutant mice.
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DISCUSSION
There is mounting evidence that gliosis contributes to pathogenesis of
neurodegenerative diseases. Blocking this process in mouse models for Alzheimer's and
ischemia improves the pathology of these mice (Kuhn et al., 1986; Cole et al., 1993;
Patel et al., 1993; Lim et al., 2000; Jantzen et al., 2002; Antezana et al., 2003; Yan et al.,
2003). For this reason, it is not surprising that many therapies for neuronal injury focus
on blocking the gliotic response. Little is known about the molecular mechanisms
involved in triggering or sustaining a proper gliotic response.
In this study, we present a novel role for E2F6 in gliosis. Gliosis is suppressed in
eight-week-old E2f6 mutant mice with neuronal injury induced by Bmil loss and five-
day-old E2f6 mutant pups injected with a neurotoxin (MAM). In E2f6-' pups injected
with MAM, the phenotype was partially penetrant, with five out of seven E2f6' pups
showing a suppression of gliosis. Gliosis was not suppressed in five-day-old E2f6/ pups
deficient for Bmil. We hypothesize that there is a threshold level of gliotic activity that
E2f6 loss can suppress. To further investigate these results, it would be interesting to do a
whole-genome analysis of mRNA changes in brain extracts of wildtype and E2f6 mutant
mice subjected to brain injury. Finally, it will be important to investigate whether E2f6
loss modulates the gliosis and neurodegenerative phenotypes of mice with Alzheimer's
disease.
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EXPERIMENTAL PROCEDURES
Immunohistochemistry
Slides were dewaxed and rehydrated. Antigen unmasking was done by boiling
slides for 15 minutes in 10mM Sodium Citrate/0.05% Tween, pH6. Slides were cooled
for 15 minutes at room temperature and then washed in water three times for five minutes
each wash. To block endogenous peroxidases, slides were blocked in 1% hydrogen
peroxide for 20 minutes, washed with water 3 times for five minutes each wash, and PBS
one time for five minutes. Next was a blocking step with 5% goat serum in PBS for 1
hour at room temperature. The primary antibody GFAP (DakoCytomation, Z0334, Rabbit
polyclonal, diluted 1:1000) or Ki67 (BD biosciences, 347580 and 550609, diluted 1:50)
was diluted in blocking solution (5% goat serum in PBS) and incubated overnight at 40 C.
The following day, slides were washed three times in PBS for five minutes each wash.
Secondary antibody (Vectastain ABC kits, vector laboratories) was diluted 1:500 in
block, and slides were incubated with the secondary antibody for 1 hour at room
temperature. A DAB substrate was used for the detection per manufacturer's instructions
(Vector laboratories). Following the detection, slides were counterstained with Harris
Hemotoxin and mounted using standard protocols.
TUNEL Staining
TUNEL staining was performed using a In Situ Cell Death Detection Kit, AP
(Roach, 11684809910). Slides were dewaxed. An antigen retrieval step was performed by
boiling the slides in 10mM Sodium Citrate/0.05% Tween, pH6 for fifteen minutes.
TUNEL staining was performed per manufacturer's instructions (Roach, 11684809910).
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Methylazoxy methanol acetate injections
Mice at postnatal day three were injected subcutaneously with 43mg/kg of MAM
(NCI Repository, NCI# F0040, MRI# 213) dissolved in physiological saline at 2mg/ml.
A maximum volume of 100 microliters was injected. Two days later, mice were
euthanized by carbon dioxide inhalation followed by either decapitation or opening of the
thorax. Brain tissues were collected for histological analyses. The cage bedding and
carcasses were handled as biohazardous materials, and the cage was washed with sodium
bicarbonate.
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Chapter 4
Discussion
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E2F6 is a repressor of transcription (Morkel et al., 1997; Gaubatz et al., 1998;
Trimarchi et al., 1998) that has been shown to biochemically interact with members of
the mammalian polycomb group family of proteins (Attwooll et al., 2004). Little is
known about the biological role of E2F6 in development and polycomb repression. Thus,
to investigate E2F6's role in vivo, we generated mice deficient for E2f6. E2f6 mutant
mice display subtle axial skeletal transformations. These include the T13-L1 and L6-S 1
posterior axial skeletal transformations (Storre et al., 2002; Courel et al., 2008). MEFs
isolated from E2f6' mice do not have any proliferation or cell cycle defects (Storre et al.,
2002). Compound mutants of polycomb group proteins have been generated in mice. The
result of this is often an exacerbation of the phenotypes of the single mutants (Bel et al.,
1998; Akasaka et al., 2001; Kwon et al., 2003; Courel et al., 2008). We bred mice
deficient for both E2f6 and Bmil in order to further define E2F6's role in polycomb-
mediated repression.
Bmil is a core component of polycomb repressive complex one (PRC1), (Saurin
et al., 2001; Levine et al., 2002) and has been shown to interact biochemically with E2F6
(Trimarchi et al., 2001). This complex maintains the repressive state of the Hox genes.
Bmil mutant mice display the same T13-L1 and L6-S1 axial skeletal transformations that
E2f6 mutant mice have (van der Lugt et al., 1994). Mice deficient for Bmil also display
other posterior transformations, including E, C1-C2, C7-T1, and T7-T8 (van der Lugt et
al., 1994). Additionally, Bmil loss compromises the proliferative capacity of primary
cells. MEFs deficient for Bmil exhibit an impairment in proliferation, a defect in cell
cycle re-entry, and premature senescence (Core et al., 1997; Jacobs et al., 1999b; Courel
et al., 2008). Loss of Bmil in vivo results in neural and hematopoietic defects due to the
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impaired proliferation and self-renewal of stem cells from these compartments (van der
Lugt et al., 1994; Jacobs et al., 1999b; Molofsky et al., 2003). The impaired proliferative
properties seen in vitro and in vivo can be partially attributed to the deregulation of the
Ink4a-Arflocus (Jacobs et al., 1999b; Molofsky et al., 2005). Mice deficient for both
Bmil and Ink4a-Arfhave a partial rescue of the hematopoietic and neural defects and a
complete rescue of the in vitro defects of MEFs (Jacobs et al., 1999a; Molofsky et al.,
2005).
Ink4a-Arf encodes two proteins, p16INK4a and p 9 ARF, which regulate cellular
proliferation and apoptosis. Bmil directly represses Ink4a-Arf, and Bmil loss results in a
derepression of this locus (Kotake et al., 2007). E2F proteins have also been shown to
play a role in the regulation of Ink4a-Arf(Aslanian et al., 2004). Thus, to test for a
genetic interaction between E2F6 and Bmil in Ink4a-Arf and Hox regulation, we
generated mice deficient for both of these genes.
1. E2F6 is not involved in the regulation of Ink4a-Arf
To investigate possible synergy between E2F6 and Bmil in the regulation of the
Ink4a-Arflocus, we did a thorough analysis of tissues and cells that affected by Bmil-
loss. Despite the documented role of various E2F family members in the regulation of Arf
(Aslanian et al., 2004), we did not detect any evidence that E2F6 contributes to the
regulation of the Ink4a-Arf locus. First, E2F6-loss had no detectable effect on the
proliferation properties of MEFs, and there was no detectable derepression of pl 9 ARF .
Second, we observed no further derepression of p16INK4a and p 1 9 ARF in E2f6';BmilJ-
versus Bmil' MEFs and no significant difference in the proliferative or senescent
properties of these two genotypes. Finally, E2F6 was not detected at the promoter of Arf
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in ES cells. We did find that Bmil deficient cells have a cell cycle re-entry defect that has
not been previously reported. However, the compound mutant cells do not differ
significantly in their ability to re-enter the cell cycle. Previously, E2F4 had been shown to
compensate for loss of E2F6 at the promoters of cell cycle genes (Zhu et al., 2004), and
one hypothesis was that a lack of a genetic interaction between E2F6 and Bmi 1 could be
due to E2F4 or another E2F family member compensating for the loss of E2F6 at Arf.
However, E2F6 was not found to occupy the Arfpromoter in wildtype ES cells. This
suggests that E2F6 plays little or no role in the direct regulation of Ink4a-Arf. Certainly,
our data show that E2F6 is fully dispensable for the appropriate regulation of this locus.
Consistent with this finding, the loss of E2F6 did not exacerbate the defects in either the
hematopoietic compartment or the cerebellar development of the Bmil mutant mice that
largely result from the derepression of Ink4a-Arf. Thus, these data suggest that E2F6
does not influence the regulation of Ink4a-Arfby Bmil by either direct or indirect
mechanisms.
2. E2F6 and Bmil co-regulate Hox genes and synergize in axial skeletal development
Our analysis of Hox gene regulation and axial skeleton transformations clearly
indicate that E2F6 and Bmil synergize in the regulation of the Hox genes. E2f6 mutation
increased the severity of Bmil-' skeletal defects in a dosage-dependent manner. Deletion
of only one allele of E2F6 was sufficient to increase the penetrance of C 1-C2, partial C7-
T 1, T 13-L1, and L6-S 1 transformations. Further deletion of the remaining allele led to an
even higher penetrance, indicating that E2F6 and Bmil synergistically contribute to these
abnormalities. In addition to the increase in axial skeleton transformations, we have also
described a novel C5 to C6 mutation where the spineous process normally present on C6
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is now present on C5. This transformation was present in 10% of E2f6 -' mice and 23% of
E2f6'-;Bmil -'- mice.
To determine if the increase in penetrance of the axial skeleton transformations
results from further Hox gene deregulation, we analyzed the expression level and
promoter occupancy of different Hox genes. Loss of E2f6 led to further deregulation of
HoxB6 and HoxCIO, but not HoxA9. To complement this analysis, we analyzed by
chromatin immunoprecipitation the promoter occupancy of Hox genes in embryonic stem
cells. Both E2F6 and Bmil were found at HoxAlO and HoxAll, but only Bmil was
bound at HoxA7. These results clearly support the conclusion that E2F6 and Bmil
synergize in axial skeletal development.
3. Regulation of Hox genes and chromatin by PcG proteins
Studies of mice deficient for polycomb group proteins specifically reveal that
mutation of one or two PcG proteins results in the deregulation of a subset of the thirty-
nine Hox genes (Goebl, 1991; van der Lugt et al., 1994; Akasaka et al., 1996; Satijn et al.,
1997; Schoorlemmer et al., 1997; Bel et al., 1998; Katoh-Fukui et al., 1998; del Mar
Lorente et al., 2000; Akasaka et al., 2001; Storre et al., 2002; Wang et al., 2002; Courel et
al., 2008). This result underscores the complexity of Hox gene regulation and the
dynamic nature of the polycomb repressive complexes. It also disputes the accepted
claim that there is a "core" PRC complex. Instead, the diverse axial skeletal phenotypes
could result from the fact that there are many different variations of PRC complexes that
differ slightly in their composition. These different PRC complexes could confer a
different level of repression on their target genes. Studies of the roles of Bmi 1 and Mel-
18 complexed with Ring 1 lend some support for this argument. Mel-18 has been shown
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to partially compensate for Bmil loss in PRCl complexes. Specifically, Mel-18 can
substitute for Bmil in maintaining PRC1 complex integrity, but a Mel-18-Ringl complex
lacks the histone ubiquitinase activity that a Bmil-Ringl complex contains (Cao et al.,
2005). While the Mel-18-Ringl complex was only found in the absence of Bmil, this
result doesn't occlude the theory that this complex could exist in vivo at a low abundance.
Therefore, this complex could potentially confer a different level of repressive activity on
target genes.
Polycomb group proteins are known regulators of chromatin structure. Some PcG
proteins can directly modify chromatin while others have been shown to bind directly to
chromatin marks. EZH2, a component of the polycomb repressive complex 2 (PRC2),
contains a SET domain and exhibits histone methyl transferase activity to histone H3 at
lysine 27 (Cao et al., 2002; Czermin et al., 2002; Kuzmichev et al., 2002; Muller et al.,
2002). This methyl mark is involved in the recruitment of PRC 1. The PcG protein,
polycomb (HPC in humans, M33 in mice), can bind directly to methylated lysine 27 of
histone H3 (Cao et al., 2002; Muller et al., 2002). Therefore, H3K27 methylation
facilitates recruitment of the polycomb protein (Pc) and mediates targeting of the PRC1
to PcG targets. Recently, it has been shown that PRC1 can ubiquitinate histone H2A.
Specifically, Ringla and Ringlb exhibit E3 ubiquitin ligase activity towards histone H2A
(de Napoles et al., 2004; Wang et al., 2004; Cao et al., 2005). It was subsequently
discovered that RYBP, another PcG protein, binds directly to ubiquitinated H2A in vivo
(Arrigoni et al., 2006). It is still unknown exactly how the concerted action of H3K27
methylation and H2AK119 ubiquitination serves to repress chromatin. There is evidence
to suggest the H2AK 119 ubiquitination and RYBP binding serves to recruit another
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histone modifier, Suv420. This histone methyltransferase was found to interact with
RYBP in a yeast two-hybrid screen (JA Lees, unpublished data). Suv420 methylates
histone H4 at lysine 20 (Schotta et al., 2004). Additionally, H4K20 methylation is
downstream of H3K27 methylation at the inactive-X chromosome (Schotta et al., 2004).
These published and unpublished results suggest a mechanism in which RYBP recruits a
Suv420-containing complex to PcG targets (Figure 1). This methyl mark could lead to a
very condensed state of chromatin. It is clear that a "histone code" plays a vital role in the
regulation of chromatin. PcG complexes are at the core of this regulation, and their roles
in regulation of transcription reach far beyond Hox genes.
4. E2F6 in the regulation of gliosis
Mice deficient for E2f6 fail to undergo a proper gliotic response after neural
damage (Chapter 3). Gliosis is a process in the brain that occurs in response to trauma or
neuronal injury. The hallmark of gliosis is astrocyte activation, characterized by an
increase in an intermediate filament protein, GFAP. There is evidence to suggest that
gliosis is both neuroprotective and harmful after brain trauma. Astrocytes play a pivotal
role in scavenging potentially toxic agents from the extracellular matrix (Aschner and
Kimelberg, 1991; Sano et al., 1997; Marcus et al., 1998; Anderson and Swanson, 2000;
Dringen, 2000; Dringen and Gutterer, 2002). After neuronal injury, this function of
astrocytes lends acute protection to the surrounding neurons. However, there is increasing
evidence that gliosis exacerbates the pathologies of individuals with neurodegenerative
diseases. In a mouse model for Alzheimer's disease, anti-inflammatory drugs such as
ibuprofen have been shown to suppress the gliotic response and reduce amyloid plaque
formation (Lim et al., 2000; Jantzen et al., 2002; Yan et al., 2003). Similarly, dispensing
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ibuprofen to mice or rats subjected to ischemia reduces neuronal injury and improves
cerebral blood flow and neurological outcome (Kuhn et al., 1986; Cole et al., 1993; Patel
et al., 1993; Antezana et al., 2003). These studies make the gliosis process a particularly
interesting therapeutic target. However, little is known about the molecular mechanisms
involved in triggering and sustaining a gliotic response.
There is some suggestion that neural injury induced by neurodegenerative
diseases, tumorigenesis, and ischemia initiates inappropriate activation of a program
required for development of the central nervous system (Liu et al., 2006). In this
intriguing model, EGFR is inappropriately activated after neural damage. In the
developing central nervous system, the EGFR regulates astrocyte migration and
differentiation of neural precursor cells into astrocytes (Miettinen et al., 1995; Sibilia and
Wagner, 1995; Kornblum et al., 1998). This pathway is reactivated during
neurodegeneration, ischemia, and tumorigenesis (Birecree et al., 1988; Planas et al.,
1998; Jin et al., 2002; Hayashi et al., 2004). EGFR regulates genes related to reactive
astrocytes and neural disorders. These genes include those involved in extracellular
matrix organization, cell migration, and cytokine production (Liu and Neufeld, 2004). In
response to EGFR, astrocytes produce transforming growth factor 3, brain-derived
neurotrophic factor, fibroblast growth factor 2, and nerve growth factor 1, which may all
be beneficial to the survival of neurons (Liu et al., 2006). However, activation of EGFR
generates chondroitin sulfate proteoglycans and laminin, both of which interfere with
axon regeneration after neural injury (McKerracher et al., 1996; Anderson et al., 1998;
Koprivica et al., 2005). This interesting theory is consistent with the duality of the gliotic
124
response. Specifically, activation of the EGFR pathway and activation of a gliotic
response present both protective and harmful attributes to surrounding neurons.
During the course of our analysis of E2f6 mutant mice, we discovered that these
mice are defective in a proper gliotic response after neural injury. Gliosis is suppressed in
eight-week-old E2f6 mutant mice with neuronal injury induced by Bmil loss and five-
day-old E2f6 mutant pups injected with a neurotoxin (methylazoxymethanol - MAM). In
E2f6-' pups injected with MAM, the phenotype was partially penetrant, with five out of
seven E2f6' pups showing a suppression of gliosis. Gliosis was not suppressed in five-
day-old E2f6' pups deficient for Bmil. We hypothesize that there is a threshold level of
gliotic activity that E2f6 loss can suppress.
5. Possible molecular mechanisms of E2F6's role in gliosis
The molecular mechanism of how E2f6 loss suppresses gliosis is unknown. To
investigate this, the ideal experiment would be a microarray from E2f6 deficient and
wildtype brain extracts after neural injury. While this has not been done, other
microarrays with different E2f6'- cell types have been performed (Oberley et al., 2003;
Pohlers et al., 2005; Storre et al., 2005). In these experiments, there is one gene in
particular that may provide insight into the mechanism of how E2f6 loss suppresses
gliosis. Oberley et al. identified Art-27 as a gene whose mRNA transcript increases in
human 293 cells transfected with a siRNA targeted to E2F6 (Oberley et al., 2003). They
subsequently verified E2F6's regulation of this gene by demonstrating that E2F6 can
directly bind to the promoter of Art-27 (Oberley et al., 2003). Art-27 is a coactivator of
the androgen receptor (AR), and when Art-27 is overexpressed, the transcriptional
activity of the AR is increased (Markus et al., 2002). Interestingly, administering
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gonadal hormones down-regulates reactive gliosis after a penetrating injury (Garcia-
Estrada et al., 1993). Clinical and experimental studies suggest a neuroprotective role for
gonadal steroids after neurological injury or disease (Jones et al., 1999; Garcia-Segura et
al., 2001). The suppression of the gliotic response after administering gonadal hormones
is strikingly similar to the suppression of the gliotic response in animals deficient for
E2f6. Therefore, a likely mechanism of E2F6's requirement in the gliotic response is
through the regulation of Art-27 and androgen receptor transcriptional activity.
Measuring the levels of Art-27 in mice deficient for E2f6 and Bmi 1 can easily test this
model. Also, chromatin immunoprecipitation from the brains of wildtype and E2f6'
deficient mice can be used to determine if E2F6 regulates Art-27 in neural cell types.
Gliosis plays a role in neurodegenerative disorders, and blocking the gliotic
response is beneficial for mice in models of Alzheimer's disease and ischemia (Kuhn et
al., 1986; Cole et al., 1993; Patel et al., 1993; Lim et al., 2000; Jantzen et al., 2002;
Antezana et al., 2003; Yan et al., 2003). Therefore, an interesting experiment would be to
cross mice deficient for E2f6 to a mouse model of Alzheimer's disease. It will be
important to determine whether the gliotic response is also attenuated in these mice and
whether E2f6 loss modulates the pathology of these mice. In conclusion, the gliotic
response occurs in response to any neural damage. Most research done in this area
suggests that this process has more harmful effects than neuroprotective effects. A better
understanding of the molecular mechanisms underlying the gliotic response will likely
lead to more effective therapies for neural damage.
126
6. Concluding Remarks
This thesis describes the role of E2f6 in axial skeletal development and gliosis.
E2F6 acts as a transcriptional repressor and can participate in polycomb mediated
repression of PcG target genes. Mice deficient for E2f6 exhibit posterior axial skeletal
transformations. This phenotype reflects E2F6's role in the regulation of Hox genes.
Additionally, these mice exhibit a suppression of gliosis after neural damage. This
phenotype may be due to a deregulation of the Art-27 gene and an activation of the
androgen receptor. The in vivo studies presented here uncover the biological function of
E2f6 in mammalian development and propose a novel role for this gene in the regulation
of neurodegeneration.
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E2F3a and E2F3b make overlapping but different contributions to total E2F3 activity.
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ABSTRACT
The E2F transcription factors are key downstream targets of the retinoblastoma
protein tumor suppressor that control cell proliferation. E2F3 has garnered particular
attention because it is amplified in various human tumors. E2f3 mutant mice typically die
around birth and E2f3-deficient cells have a proliferation defect that correlates with
impaired E2F-target gene activation and also induction of pl9Arf and p53. The E2f3 locus
encodes two isoforms, E2F3a and E2F3b, which differ in their N-termini. However, it is
unclear how E2F3a versus E2F3b contributes to E2F3's requirement in either
proliferation or development. To address this, we use E2f3a- and E2f3b-specific
knockouts. We show that inactivation of E2F3a results in a low penetrance proliferation
defect in vitro whilst loss of E2F3b has no effect. This proliferation defect appears
insufficient to disrupt normal development since E2f3a and E2f3b mutant mice are both
fully viable and have no detectable defects. However, when combined with E2fl
mutation, inactivation of E2f3a, but not E2f3b, causes significant proliferation defects in
vitro, neonatal lethality and also a striking cartilage defect. Thus, we conclude that E2f3a
and E2f3b have largely overlapping functions in vivo and that E2f3a can fully substitute
for E2fl and E2f3 in most murine tissues.
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INTRODUCTION
The retinoblastoma protein (pRB) was the first identified tumor suppressor.
pRB's tumor suppressive activity is largely dependent on its ability to regulate the E2F
transcription factors. E2Fs control the cell cycle dependent transcription of genes that
encode key components of the cell cycle machinery (Attwooll et al., 2004; Dimova and
Dyson, 2005). pRB, and its relatives p107 and p130, bind to E2fs in quiescent cells and
this prevents transcription of E2F target genes via binding to the transactivation domain
and blocking its function and by recruiting chromatin regulators which directly repress
transcription (Attwooll et al., 2004; Dimova and Dyson, 2005; Blais and Dynlacht,
2007). Dissociation of E2F/pocket protein complexes is triggered by mitogen-induced
phosphorylation of the pocket proteins by cyclin dependent kinases, Cdks, thus allowing
activation of target gene transcription by E2Fs (Trimarchi and Lees, 2002; Attwooll et
al., 2004; Dimova and Dyson, 2005). The majority of human tumors carry mutations that
either inactivate the retinoblastoma gene or activate the Cdks that mediate pocket protein
phosphorylation. This strongly suggests that the pocket-protein associated E2Fs, E2F1-5,
play an important role in tumorigenesis.
The prevailing view is that individual E2F proteins are preferentially involved in
either the activation or repression of E2F-responsive genes. E2F4 and E2F5 play a key
role in gene repression whilst E2F1 and E2F2 play a key role in activating E2F-target
genes (Trimarchi and Lees, 2002; Attwooll et al., 2004; Dimova and Dyson, 2005). E2f4
and E2f5 are expressed constitutively but E2F1 and 2 levels increase upon cell cycle re-
entry because E2fl and E2J2 are E2F-responsive genes. E2f3 is unusual in that it encodes
two different proteins, E2F3a and E2F3b (He et al., 2000; Leone et al., 2000). These
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isoforms are generated by two separate promoters that govern the expression of
alternative first exons that are spliced to a common second exon (Adams et al., 2000).
E2F3a shares many of the properties of E2FI and E2F2: it is inhibited by pRB in
quiescent cells, recruits coactivators to E2F-responsive genes in GI and its promoter is
E2F-responsive. E2f3b is constitutively expressed, like E2f4 and E2f5, suggesting that it
could function as a transcriptional repressor (Adams et al., 2000). However, in other
regards, E2F3b more closely resembles the activating E2Fs. It lacks the nuclear export
signals that are characteristic of the repressive E2Fs and thus remains in the nucleus after
release from pocket proteins. E2F3 also associates specifically with pRB, and not p107
and p130, in vivo. Importantly, recent studies have linked E2f3 amplifications to the
development of human bladder, lung and prostate tumors (Feber et al., 2004; Foster et
al., 2004; Oeggerli et al., 2004; Cooper et al., 2006; Oeggerli et al., 2006; Hurst et al.,
2007).
We previously generated an E2f3 mutant mouse strain that disrupts expression of
both E2F3a and E2F3b. A large proportion of the E2f3-deficient mice die in utero or as
neonates (Humbert et al., 2000; Cloud et al., 2002). Analysis of mouse embryonic
fibroblasts (MEFs) shows that loss of E2f3 impairs both asynchronous proliferation and
mitogen-induced cell cycle re-entry (Humbert et al., 2000). This latter defect correlated
with two changes in gene regulation. First, there is a clear defect in the transcriptional
activation of E2F-responsive genes (Humbert et al., 2000). This is consistent with the
notion that E2F3a, and also possibly E2F3b, contribute to gene activation. Second,
E2F3-loss is sufficient to derepress the Arftumor suppressor, triggering activation of p53
and expression of the cdk-inhibitor p21C ipl (Aslanian et al., 2004). In wildtype MEFs, the
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Arf promoter is specifically occupied by E2F3b, and not other E2Fs, suggesting that
E2F3b contributes to Arf repression in vivo (Aslanian et al., 2004). These observations
offer two distinct mechanisms by which E2F3a and/or E2F3b could promote proliferation
and tumorigenesis. Given these findings, we have generated E2f3a or E2f3b mutant
mouse strains to determine how each of these isoforms contributes to E2F3's key roles in
cellular proliferation and normal development.
RESULTS
E2F3b binding to the Arf promoter is not required for Arf repression.
To create E2f3a- and E2f3b-specific mutants we used recombineering to replace
the relevant ATG translation start codon with a single loxP sequence (Figure lA and
Supplementary Information). ES cell lines shown to be correctly targeted by Southern
blotting (Figure ib) were used to produce E2f3a and E2f3b mutant mouse strains in both
mixed (C57BL/6 x 129S/v) and pure 129S/v genetic backgrounds. Our first goal was to
verify the specificity of our mutation strategy. To this end, we generated MEFs from
mutant and wildtype littermates and conducted western blotting using a pan-E2F3
antibody, LLF3#2G2, which recognizes a C-terminal sequence common to both E2F3
isoforms (Parisi et al., 2007). This analysis confirmed that the introduced mutations
specifically abolished the expression of either E2F3a or E2F3b (Figure Ic). Moreover,
there was no detectable change in the levels of the remaining E2F3 isoform (Figure 1c) or
in the levels of E2F1 or E2F4 (data not shown).
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Figure 1: Mutation of E2f3a or E2J3b by gene targeting.
(a) Schematic of the targeting construct and the endogenous E2f3 locus. The E2f3a and
E2f3b exons are represented by the shaded boxes. The common second exon is 65kb
from these exons. DTa represents the diphtheria toxin negative selection cassette and
loxPneo the loxP site flanked PGKEM7neobpA positive selection cassette. The two loci
after the predicted homologous recombination event are shown for E2f3a and E2f3b. The
two lines underneath the E2f3 locus represent the 5' and 3' probe sequences used for
Southern analysis of the homologous recombination event. (b) The predicted sizes of the
genomic DNA fragments identified by these probes are shown along with Southern
analysis of representative targeted clones. In each case one targeted clone and one non-
targeted clone is shown. (c) Western blotting analysis of protein extracts derived from
mouse embryo fibroblasts (MEFs) of the indicated genotypes. In wildtype MEFs, both
E2F3a and E2F3b are detected. Both of these isoforms run as doublets. In E2f3 mutant
MEFs both isoforms are absent. Mutation of E2f3a or E2f3b leads to specific loss of only
the mutated isoform indicating that the targeting strategy successfully disrupted
expression of each isoform separately.
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Our previous studies showed that E2F3 mutation lead to the induction of Arf in
MEFs, and implicated the E2F3b isoform as a direct transcriptional repressor of Arf
(Aslanian et al., 2004). Thus, we wanted to establish how the loss of either E2F3a or
E2F3b affects the regulation of Arf. First, we performed chromatin immunoprecipitation
(ChIP) experiments to examine E2F binding to the Arf promoter in MEFs derived from
E2f3a-' or E2f3b-'- embryos alongside their wildtype littermate controls (Figure 2). We
used a pan-E2F3 antibody for these studies to allow direct comparison of the binding of
E2F3a versus E2F3b. Consistent with our previous studies, we found that Arfis
specifically bound by E2F3 in wildtype MEFs. This is in clear contrast to a classic E2F-
responsive gene, p107, which shows significant occupancy by both E2F3 and E2F4. As
expected, mutation of E2f3a did not alter the anti-E2F3 ChIP signal detected at Arf
(Figure 2a). This supported our prior conclusion that E2F3b is the major E2F bound to
Arf in MEFs but it does not preclude the possibility that both E2F3a and E2F3b can
occupy the Arf promoter in wildtype MEFs. In the absence of E2F3b, we now observed
ChIP signals with antibodies to E2F3, E2F4 and, to a lesser extent E2F1, at Arf (Figure
2b). Similar results were observed in three other isoform specific mutant lines analyzed
(data not shown). Thus, we conclude that E2F3a, and also other E2Fs, are able to bind to
the Arf promoter in place of E2F3b in E2f3b-' MEFs.
To determine whether the loss of E2F3b or E2F3a increases the levels of p1 9Arf
and p21Cipl as observed in E2f3 and E2fl;E2J2;E2f3 mutant MEFs (Wu et al., 2001;
Aslanian et al., 2004; Sharma et al., 2006; Timmers et al., 2007), we analyzed the levels
of these proteins in serum starved mutant and wildtype MEFs generated from littermate
embryos. We conducted these studies using both mixed (C57BL/6 x 129Sv) and pure
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129Sv background MEFs, since the E2f3 mutant phenotype is always stronger in the pure
129Sv background (Cloud et al., 2002). Irrespective of the genetic background, the levels
of p19A f or p21 cipl were not elevated in the E2f3b mutant cells (n=8 independent mutant
cell lines) relative to wildtype littermate controls (Figure 2d). The mixed (C57BL/6 x
129Sv) background E2f3aA- MEFs did not display any detectable defect in this, or any
other, assay (data not shown). In contrast, the pure 129Sv background E2f3a/- MEFs
showed somewhat variable phenotypes. Five of the six lines tested showed either no
upregulation of either p19" or p2 Cipl, or they had slightly elevated levels of just one of
these proteins (Figure 2c, data not shown). The remaining line had increased levels of
both Arf_and p21 (Supplementary Figure 1). These changes are subtle. However, the
E2F3a-deficient MEFs seem to be more predisposed to upregulate p19f and/or p21CiPl
than wildtype controls. Taken together, these data show that the robust activation of the
pl 9 Arf-p 5 3 -p2 1Cpl network that occurs in E2f3 mutant MEFs cannot be reproduced by the
loss of either E2F3b or E2F3a. Since E2F3b is the predominant Arfpromoter binder in
wildtype cells but E2F3a takes its place in E2f3b-deficient MEFs and Arf and p21
regulation is subtly impaired in E2f3a-deficient MEFs, we conclude that E2F3a and
E2F3b can play overlapping roles in the appropriate regulation of the p19A-p53-p21Cipl
network.
E2F3a and E2F3b play overlapping roles in controlling asynchronous proliferation
and cell cycle entry.
E2f3-loss impairs the proliferation properties of MEFs and this correlates with
both the derepression of Arf and the failure to appropriately induce classic E2F-
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Figure 2: Arf promoter regulation,
p 1 9 Arf and p21 °C pl expression and
asynchronous proliferation properties
of E2f3a- and E2J3b-deficient MEFs.
(a) Chromatin immunoprecipitation (ChIP)
was performed using asynchronously
proliferating wildtype and E2f3a'
littermate MEFs, or (b) wildtype and
E2f3b /' littermate MEFs. Sonicated cross-
linked chromatin was immunoprecipitated
with antibodies to E2F3, E2F1, E2F4, or
control IgG. The purified DNA was
analyzed by PCR with primers specific for
the p107 or Arf promoters, or a control
sequence lacking E2F binding sites (lkb
upstream of a control promoter). Input,
0.5% of chromatin in IP reaction was
analyzed by PCR. These analyses show
that in the absence of E2F3b, E2F3a is
detected bound to the Arf promoter. (c)
The majority of E2f3a mutant MEFs show
little or no increase in pl 9 Arf and p21Cipl
levels relative to wildtype controls, as
illustrated by western blot analysis of two
representative sets of serum arrested
MEFs. GAPDH is shown as a loading
control. (d) No increase in p 19"' or p21Cip0
levels are observed in E2f3b mutant MEFs
relative to wildtype littermate controls. (e)
E2f3a--, E2f3a +' and E2f3a'l' MEFs or (f)
E2f3b--, E2f3b+', and E2f3b +'/ MEFs were
assayed for asynchronous proliferation.
dish and their growth monitored by daily
counting for six days. No significant growth defect was observed in the isoform specific
mutant cells.
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responsive genes (Humbert et al., 2000; Aslanian et al., 2004). Having shown that loss of
E2F3a or E2F3b results in occasional or no increase in p19" and p21 cip1 levels
respectively, we wished to assess whether cell proliferation was compromised. To test
this we compared the properties of mutant versus wildtype MEFs in standard
proliferation assays, and also assayed their ability to re-enter the cell cycle from a serum
starvation-induced quiescent state. The vast majority of the E2f3b mutant MEF lines had
proliferation properties that were indistinguishable from the controls irrespective of
whether they were generated in the mixed (6/7 lines tested) or pure 129Sv (6/7 lines
tested) genetic backgrounds (Figure 2f shows representative lines). Moreover, none of the
three of E2f3b mutant lines tested in cell cycle re-entry experiments showed any
detectable defect in the kinetics of cell cycle progression, as judged by analysis of BrdU
incorporation (Figure 3a shows a representative line). In tandem with this analysis, we
also assessed mRNA expression levels of three E2F target genes, Cyclin E, Cyclin A and
p107 as well as Arf and p21cJ p'. Consistent with lack of proliferation and re-entry defects,
we saw no significant difference in levels of these mRNAs in control versus E2f3b6
MEFs using two independent sets of lines (Figure 3b and data not shown). Thus, we
conclude that E2F3b-loss has no dramatic affect on either Arflevels or cell cycle
regulation.
As with our analysis of Arf regulation, the properties of the E2f3a-' MEFs were
more variable. The majority (4/6) of the pure background E2f3a-' lines showed no
detectable defect in asynchronous proliferation (Figure 2e shows two representative
lines). Accordingly, their kinetics of cell cycle re-entry and regulation of Cyclin E, Cyclin
A, p107, Arf and p21 mRNAs was similar to that of wildtype littermate controls (Figure
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3; data not shown). In contrast, two of the six E2f3a /- lines grew more slowly than the
wildtype littermate lines in asynchronous proliferation assays (Supplementary Figure 1).
They also had a significant defect in cell cycle re-entry and this was associated with a
failure to appropriately induce the transcription of classic E2F-responsive targets
(Supplementary Figure 1). Importantly, one of these cells lines had an associated
upregulation of Arf and p21 but the other showed little change in these mRNAs
(Supplementary Figure 1). Given these findings, we conclude that E2f3a/ MEFs have a
partially penetrant phenotype that can affect both the pl9Af-p53-p2lCi'P' network and cell
cycle regulation. In one E2f3a/- cell line, the defects in E2F target induction and cell
cycle progression appeared to be independent of changes in Arf and p21 expression,
suggesting that these events can be uncoupled. Finally, our data show that the loss of
either E2F3a or E2F3b has far less impact on cell cycle regulation than the combined loss
of both E2F3 isoforms (Humbert et al., 2000), indicating that these two proteins, or other
members of the E2F family, can largely substitute for one another in the regulation of cell
cycle genes.
Neither E2J3a nor E2f3b are required for viability
To assess the role of E2F3a in normal development, E2f3a'l animals were
intercrossed in either a mixed (C57BL/6xl29Sv) or 129Sv background. A similar
strategy was used to test the consequences of mutating the E2f3b allele. In each case the
frequency of mutant animals was not statistically significantly different from the
expected Mendelian frequency (Table 1 and 2). This is in contrast with the mutation of
E2f3 (both a+b isoforms) which results in reduced viability in a mixed background and
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Figure 3: Cell cycle re-entry
properties of E2J3a- and E2j3b-
deficient MEFs.
E2f3a' and E2f3b' MEFs were serum
starved (To) and induced to enter into
the cell cycle with serum alongside
wildtype littermate controls. (a) Entry
into the cell cycle was analyzed by
BrdU incorporation at the indicated
times (hours) followed by propidium
iodide staining and FACS analysis, the
percentage of cells in S-phase (BrdU
labeled) is plotted. (b) Quantitative PCR
analyses of the mRNA levels of Arf and
p21 as well as the E2F target genes
Cyclin E, Cyclin A and p107 during the
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embryonic lethality in a 129Sv background (Humbert et al., 2000; Cloud et al., 2002). In
addition, histological analyses of E2f3a-' adults and E2f3b' adults (n=8 mutant animals
of each isoform, 4 of each sex) in comparison with wildtype littermates on either
background did not identify any distinct pathology. Additionally, no distinct phenotype
associated with either E2F3 isoform mutation has been observed in aging colonies (data
not shown).
Table 1. Mutation of E2f3a does not cause a significant reduction in viability
Background E2f3a/' observed X2 test p value
E2J3a Pure (129Sv) 23% (60/257) 0.615
E2f3a+' mice on the indicated backgrounds were crossed and the pups genotyped at three
weeks of age. The indicated frequency of mutant animals was not significantly different
from the expected frequency as judged by a 2 test.
Table 2. Mutation of E2f3b does not cause a significant reduction in viability
Background E2J3b'" observed X2 test p value
E2f3b Pure (129Sv) 33% (28/85) 0.256
E2f3b+' mice on the indicated backgrounds were crossed and the pups genotyped at three
weeks of age. The observed frequency of mutant animals was not significantly different
from the expected frequency as judged by a 2 test.
E2f3a but not E2J3b is required for viability and proliferation control in the absence
of E2fl
We have previously shown that the additional mutation of one or both E2fl alleles
causes E2f3 mutant embryos to die at progressively earlier timepoints, indicating
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significant functional overlap between E2F1 and E2F3 (Cloud et al., 2002). Thus, to
further test the relative roles of the two E2F3 isoforms, we intercrossed the E2f3a and
E2f3b mutants with E2fl mutant mice to determine the phenotypes of compound mutant
mice in a mixed (C57BL/6x129Sv) background. Remarkably, we found that E2fl'
;E2f3b /' animals were present at the expected Mendelian frequency when weaned at three
weeks of age (Table 3). Moreover, these mice were viable and fertile, and histological
analyses of E2flF-;E2f3b' (n=5) versus E2fl+';E2f3b~' (n=3) littermate controls showed
that the compound mutants did not display any defects beyond those previously reported
in the E2fl mutant animals (data not shown). Thus, E2f3b-loss does not exacerbate the
phenotypic consequences of E2fl-deficiency. In contrast, E2f3a mutation had a dramatic
effect. First, the E2fl/';E2f3a- mice were greatly under-represented (p=0.021) at three
weeks of age (Table 4). Moreover, the two surviving double mutants weighed less than
one-third of their E2ftl/ ;E2f3a'• littermates (data not shown). To determine the time of
death, we conducted E2fl] -;E2f3a÷+ intercrosses and recovered the pups at P1 for
genotyping and also histological analysis. At P1, the observed number of living E2fl'
;E2f3a/ pups was not statistically different from the expected number (Table 4). This,
along with daily monitoring of other litters, showed that the E2fl ;E2f3a compound
mutants die as neonates.
The histological analyses of P1 E2fl' ;E2f3a- pups (n=6) and paired littermate
controls did not identify any tissue specific defects that could obviously account for the
death of the E2flJ- ;E2f3a-- neonates (data not shown). Instead, we believe that this results
from their failure to thrive because of their small size. Histological analysis did, however,
reveal a striking defect in cartilage morphology in the E2fl;E2f3a compound mutants.
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Table 3. E2fl;E2f3b double mutant animals arise at the expected frequency
Cross conducted E2fll;E2J3b-" observed Expected
E2fl/T;E2f3bK x E2fl'";E2f3b'1  12.5% (2/16) 12.5%
E2fl/F'E2f3b x E2fl/';E2f/3b/' 23% (3/13) 25%
x2 test p value (sum) 0.98
The indicated crosses were performed using mice on a C57BL/6 x 129Sv background and
the pups genotyped at three weeks of age. The frequency of double mutant animals is
shown and was determined not to be statistically significantly different from the expected
frequency using a •2 test.
Table 4. Mutation of E2fl and E2f3a significantly reduces viability
Age E2fl';E2J3a'~ ' E2flF'';E2f3a -' E2fl'-;E2f3a""  X2 test p value
D 2 0 -i 
•
. .
3 Weeks old 51 89 2 0.021
Mixed (C57BL/6 x 129Sv) background E2fl-/-;E2f3a'+ mice were intercrossed and the
number of pups of each genotype was determined at the indicated ages. The observed
frequency of E2fl-' ;E2f3a/ mice was not significantly different from expected at birth
but significantly lower than expected at three weeks of age as determined by X2 test.
This was observed in various bones, including the spine, but was most apparent in the
long bones (Figure 4; data not shown). Thus, we analyzed the defect in this setting. The
E2fl'I;E2f3a/ femurs stained appropriately with Alcian Blue, indicating that mature
cartilage was formed (data not shown), but the constituent chondrocytes were
disorganized and/or displayed abnormal morphologies (Figure 4a). First, chondrocytes
within the columnar layer of E2fl;E2f3a compound mutant epiphyseal plates did not
form stacked columns typical of chondrocytes in this region, and many of the E2fl-'
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;E2f3a- cells lack the condensed "bean shape" cytoplasm that is characteristic of their
wildtype counterparts but instead had a more diffuse cytoplasm resembling pre-
hypertrophic chondrocytes (Figure 4a). Second, chondrocytes within the resting,
columnar and hypertrophic zones of the E2fl;E2f3a compound mutant femurs appear
considerably larger than those in control E2fl -;E2f3a'l  embryos (Figure 4a). To further
investigate this defect, we measured chondrocyte sizes in comparable zones of E2fJl-
;E2f3a- versus littermate control E2fl ' ;E2f3a"'÷ femurs from two different P1 litters
(Figure 4b). In each of the three zones we detected two clear differences between the two
genotypes; the E2fl-;E2f3a- chondrocytes showed a much greater range of cell sizes
than their E2fl /- littermate controls and they displayed a statistically significant 1.5-2.0
fold increase in their mean surface area (p<0.001 or <0.0001). Analyses of 18.5dpc
embryos gave identical results (Fig 4C, Supplementary Figure 2). Age-matched E2f3a
mutant embryos showed a negligible increase in cell size (1.08 fold) only in the
hypertrophic chondrocytes whilst E2fl mutant embryos showed a modest 1.2-1.4 fold
increase in cell size in all of the chondrocyte zones (Fig 4C, Supplementary Figure 2).
These results show that E2fl mutation causes a subtle chondrocyte defect and this is
exacerbated by the mutation of E2f3a. Collagen II and collagen X, markers of
chondrocytes and hypertrophic chondrocytes respectively, were both expressed in the
appropriate regions of the mutant embryos (Supplementary Figure 3). Thus, the increase
in chondrocyte size following loss of E2F activity does not appear to result from
premature activation of the hypertrophic program.
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Figure 4: Mutation of E2fl and E2f3a results in abnormal cartilage morphology.
(a) Hematoxylin and eosin stained sections of hind leg femoral epiphyses from E2fl ' and
E2fl/;E2f3a-b mutant littermate P1 pups. The zones of resting, columnar and
prehypertrophic/hypertrophic chondrocytes are shown. Cells in all three zones are larger
in E2fl;E2f3a mutants in comparison with control E2fl mutants, in addition cells within
the columnar zone are disorganized in the E2fl;E2f3a mutants in comparison with
control E2fl mutants and don't form the typical stacked columns. (b) From photographs
of E2fl mutant and littermate E2fl;E2f3a mutant femurs chondrocyte sizes in each zone
were measured and the data displayed as box plots for two representative P1 litters
illustrating the universal increase in cell size. The data was also analyzed using a
student's t-Test and, in all zones, cells in the E2fl;E2f3a mutants were statistically
significantly larger than those in the same zones of the E2fl mutants (p values indicated).
(c) Box plot analyses of chondrocyte size quantification from three or more E2fl;E2f3a
mutant embryos and littermate controls of the indicated genotypes at 18.5dpc show a
similar phenotype (left panel). A weaker but statistically significant increase in cell size is
observed in 18.5dpc E2flJ/ embryos relative to wildtype controls (middle panel). A minor
cell size increase is also seen in 18.5dpc E2f3a- embryos versus wildtype controls only
in the hypertrophic chondrocytes (right panel), p values derived from Student's t-test
analysis of the mean cell sizes are shown. (d) Quantification of proliferation markers in
resting and columnar chondrocytes at 18.5 dpc. Immunohistochemistry was used to label
cells that had incorporated BrdU or expressed Ki67. No significant difference in BrdU
labeling was detected but Ki67 was detected in a smaller percentage of cells within the
columnar layer in E2fl;E2f3a mutants relative to E2fl mutants (mean +/- s.d. and p
values indicated).
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E2F3 and E2F1 have both been linked to the regulation of proliferation and cell
death. Thus, we examined the state of both processes by screening matched femoral
sections by immunohistochemical staining for Ki67, a proliferation marker and known
E2F-responsive gene, and incorporated BrdU, to detect replicating cells, and TUNEL or
cleaved caspase 3 staining to detect apoptotic cells. Given the mild chondrocyte defect in
the E2fl/ mice, we first compared femurs from E2fl/' embryos at 18.5dpc with those of
wildtype littermate controls. In these two genotypes, we saw no statistically significant
difference in BrdU or Ki67 labeling of the cells in the resting and columnar zones (data
not shown). We could not assess cells in the hypertrophic zone, since these typically lose
their nuclei. We next compared femurs from E2fl- ;E2f3a- versus E2fl/';E2f3a"'/
littermates at 18.5dpc. There was no detectable difference in the level of apoptosis
between these two genotypes (data not shown). Similarly, there was no statistically
significant difference in the percentage of BrdU-positive cells in either the resting or
columnar zones of E2fl';E2f3a-- versus E2flj;E2f3a+'/ femurs at 18.5dpc (Figure 4d).
In contrast, analysis of adjacent sections showed the percentage of Ki67 labeled cells was
modestly decreased in the resting zone (p=0.058), and significantly decreased in the
columnar zone (p=0.015), of the E2fl/¾;E2f3a4 versus E2fl1- ;E2f3a' •' embryos (Figure
4d). We therefore conclude that the combined loss of E2F1 and E2F3a impairs the
expression of at least one E2F-target gene, Ki67, in chondrocytes. Although there is no
detectable impairment of DNA replication at this timepoint, these data suggest that loss
of E2F1 and E2F3a somehow impairs cell cycle progression.
To further explore this possibility, we generated MEFs from E2fl-';E2f3a-
embryos and compared their properties to E2fl-/ littermate controls, since it is well
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Figure 5: E2fl;E2f3a MEF lines show defects in proliferation, cell cycle re-entry and
E2F target gene induction.
(a) E2fll-;E2f3a- MEFs were assayed for asynchronous proliferation alongside E2flJ
littermate controls. Cells were plated in duplicate at 6x10 4/3cm dish and their growth
monitored by daily counting for six days. (b) E2fl/ and E2fl- ;E2f3a - littermate MEFs
were serum starved (To) and induced to enter into the cell cycle with serum. Entry into
the cell cycle was analyzed by BrdU incorporation at the indicated times (hours) followed
by propidium iodide staining and FACS analysis, the percentage of cells in S-phase
(BrdU labeled) is plotted. (c) Quantitative PCR analyses of the mRNA expression levels
of Arfand p2l during cell cycle re-entry. (d) Western blotting for pl9", p21cip1 and
GAPDH (as a loading control) in serum starved MEFs. (e) Quantitative PCR analyses of
the mRNA expression levels of the E2F target genes Cyclin E, Cyclin A and p107 in
E2fl' and E2fl --;E2f3a-l littermate MEFs during the cell cycle re-entry experiment.
Both E2fl--;E2f3a-' MEF lines showed reduced proliferation, reduced S-phase entry,
increased pl9Arf and p21Cipl expression and lower levels of E2F target gene expression.
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established that E2F1-deficiency does not significantly impair MEFs (Field et al., 1996;
Humbert et al., 2000). Three of the four E2fl' ;E2f3a' MEF lines analyzed were
impaired in both asynchronous proliferation and cell cycle re-entry (Figure 5a,b; data not
shown). Accordingly, we observed an upregulation in both Arf and p21 mRNA and
protein levels (Figures 5c,d), and poor induction of the classic E2F-responsive genes
Cyclin E, Cyclin A and p107 following cell cycle entry (Figure 5e). This spectrum of
defects is strikingly similar to that seen in E2f3-' MEFs, lacking both E2F3a and E2F3b
(Humbert et al., 2000; Aslanian et al., 2004). Consistent with the viability of E2fl'
;E2f3b-' mice, preliminary studies indicate that the E2fl-';E2f3b-' MEF lines don't have
a proliferation defect (data not shown). Taken together, these data suggest that there is
significant overlap in the functions of E2F1, E2F3a and E2F3b. Based on the relative
phenotypes of both the single mutant MEFs and the compound mutant mice, we conclude
that, of the two isoforms, E2F3a seems to play the more important role in both cell cycle
control and normal development.
DISCUSSION
The E2F transcription factors are key downstream targets of the pRB tumor
suppressor. Considerable attention has focused on E2F3 because it is amplified in a
variety of human tumors including bladder, lung and prostate tumors (Feber et al., 2004;
Foster et al., 2004; Oeggerli et al., 2004; Cooper et al., 2006; Oeggerli et al., 2006; Orlic
et al., 2006; Hurst et al., 2007). We, and others, have previously generated E2f3 mutant
mouse strains that eliminate expression of both E2F3a and E2F3b (Humbert et al., 2000;
Wu et al., 2001). Analyses of these models show that E2F3 is of central importance.
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First, E2F3 promotes the development of various tumor types (Ziebold et al., 2003;
Parisis et al., 2007). Second, it is the only E2f knockout that leads to embryonic lethality
or to a profound defect in cellular proliferation (Humbert et al., 2000; Wu et al., 2001;
Cloud et al., 2002). Notably, this proliferation defect correlates with two distinct changes:
there is an impaired activation of E2F responsive genes and also a derepression of Arf
and a consequent activation of the p5 3 -p21cipl anti-proliferative response (Aslanian et al.,
2004). Our prior analysis strongly suggested that this latter defect reflects a specific role
for E2F3b in the transcriptional repression of Arf (Aslanian et al., 2004). However, it was
unclear to what extent E2F3a versus E2F3b contributes to either the cellular or
developmental requirements for E2f3. In this study, we address this question through the
generation and analyses of E2f3a and E2f3b-specific mutant mouse strains. These
analyses show that the two isoforms have largely overlapping functions. First, the loss of
E2F3a has a low penetrance effect on the asynchronous proliferation and cell cycle re-
entry properties of MEFs. In contrast, we found that E2F3b is not required for the
appropriate repression of Arf, asynchronous proliferation, or cell cycle re-entry in MEFs.
Second, in stark contrast to the high frequency of late stage embryonic or early neonatal
lethality that results from E2f3-inactivation, we find that the E2f3a-A and E2f3b-' mice are
born at the expected frequency and they live into adulthood without any significant
pathology. Thus, these data show that the presence of either E2F3a or E2F3b is largely
sufficient to fulfill the essential role of the E2f3 locus in both the control of cellular
proliferation and normal development.
We have previously demonstrated a strong synergy between E2f3 and E2fl by
showing that the combined mutation of these genes causes lethality between day 10 and
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12 of gestation (Cloud et al., 2002). Given this observation, we further probed the relative
roles of E2F3a and E2F3b by intercrossing the isoform-specific knockouts with E2fl
mutant mice. Remarkably, we found that the E2fl-';E2f3b' double mutant mice were
fully viable and had only the limited spectrum of developmental defects that are
characteristic of the E2fl-deficient animals. Since E2fl]-;E2f3-' embryos die in mid-
gestation (Cloud et al., 2002), this shows that E2F3a can fully substitute for E2F1 and
E2F3 genes in the vast majority of murine tissues. This does not assume that E2F3a is
acting alone to mediate all of the functions of E2Fl, E2F3a and E2F3b, but that the
combination of E2F3a and the other endogenous E2F family members gives sufficient
total E2F activity to allow near normal development. Given these observations, we
conclude that the E2F network has a significant degree of redundancy and robustness,
reminiscent of that seen for other core cell cycle regulators including the cyclins and cdks
(Berthet and Kaldis, 2007). In contrast to the E2fl-';E2f3b' animals, we found that the
E2fl';E2f3a'- double mutants arise at expected frequency but die within the first few
weeks of life. Thus, at least in the context of E2F1 loss, E2F3a plays a more important
role than E2F3b in vivo. A similar result was observed in vitro: E2flJ/;E2f3a/ double
mutant MEFs exhibit a reduced level of proliferation, are impaired in their ability to re-
enter the cell cycle and fail to appropriately regulate E2F-target genes. In contrast,
preliminary analysis suggests that the E2fl';E2f3b' double mutant lines are essentially
normal, again indicating a more important role for E2F3a. It is formally possible that
E2F3a has one, or more, function(s) that are specifically shared by E2F1 and not other
E2Fs. However, we favor the hypothesis that this reflects some difference in the relative
levels, or timing of expression, of the two isoforms such that E2F3a, but not E2F3b,
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places the total E2F activity above a critical threshold. Notably, our analysis of the
E2fl;E2f3a mutant neonates also reveals an essential role for E2F1 plus E2F3a in
cartilage development. Specifically, we find that the E2fl';E2f3a-' chondrocytes have an
abnormal morphology, are not appropriately organized within the epiphysis and are
significantly larger than normal. This appears to be an exacerbation of a milder
phenotype in E2fl mutant embryos. Further experiments will be required to establish the
precise cause of these defects. However, our analysis suggests that the chondrocyte
phenotype could be due to reduced E2F target gene expression. One intriguing possibility
is that these cells have increased their size in preparation for cell division but have
trouble proceeding through the cell cycle because there is insufficient accumulation of
E2F target gene products, many of which are rate limiting for DNA replication and
mitosis.
EXPERIMENTAL PROCEDURES
Generation of mutant mouse strains
A BAC clone (19H05) containing E2f3 was obtained from a library derived from
129S6/SvEvTac genomic DNA (RPCI-22, Roswell Park Cancer Institute, Buffalo, NY,
USA) and transferred into the E.coli strain DY380 (Liu et al., 2003) for generation of
targeting constructs by recombineering (http://recombineering.ncifcrf.govl. LoxP
flanked PGKEM7neobpA cassettes were generated from PL452 by PCR (Expand High
Fidelity PCR System, Roche, Indianapolis, IN, USA) to contain 50bp of flanking
homology to either the first exon of E2f3a or that of E2f3b and inserted into the BAC
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clone via recombineering. This insertion resulted in the removal of the two in frame
ATGs and the intervening 34 codons from the first exon of E2f3a and the sole ATG from
exon one of E2f3b. Following verification by PCR a 15kb fragment of the BAC
encompassing the integrated cassette was transferred into pBR322 (NEB, Ipswich, MA,
USA ) by gap repair. This clone was transferred into the E.coli strain DH5a and a blunt
8.6kb BstXI - Hpa I fragment transferred to a EcoRV cut pBRDTAol vector containing
a diphtheria toxin negative selection cassette (DTa) using standard cloning procedures
(Sambrook et al., 1989). All modifications were verified by restriction digestion mapping
and sequencing. The resulting targeting vectors were electroporated into J1 ES cells
(derived from 129S4/SvJae) and DNA from 240 (E2f3a) and 432 (E2f3b) G418-resistant
colonies was screened by southern blotting (see below). C57BL/6 blastocysts were
injected with correctly targeted ES cells and transplanted into pseudopregnant CD1 mice.
Chimeras resulting from one E2f3a'l and two E2f3b"+ ES cell lines gave germline
transmission, as judged by southern blotting. These were mated to C57BL/6 TgN(ACTB-
cre) 2Mrt or 129S4/SvJae Tg(Prm-cre)580g mice (Jackson Laboratories, Bar Harbor,
ME, USA) to delete the loxP flanked neo cassette, as verified by southern blotting and
PCR analysis described below. The E2f3 mutant alleles were segregated from Cre
transgenes by breeding to generate E2f3a'l or E2f3b÷' strains.
Oligonucleotides (Integrated DNA Technologies) used for generating targeting
constructs.
a) Primers to amplify the loxP flanked PGKEM7neobpA cassette derived from PL452
(Liu et al., 2003) for integration into the BAC clone by recombineering had the following
sequences:
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E2f3a
1) AGCAATACGTTAATATATCGTAACACTAAAAAAGAGCAGGAGCGAGAGAT
AACTTCGTATAGCATACA
2) GGGCGGCGGCGGCGGCGAAGCCGGGGCTGGCTAGCAGTGCCCTTTTGTCA
TAACTTCGTATAATGTATG
E2f3b
1) CTCTCCAGCCGGCCCCCCACCTCCCCCGGAGCCAGGCTGCTTTCGGAAAT
AACTTCGTATAGCATACA
2) GTGGCTCGGGCCCCCGCGCGGTCCAGGTCACTAACCTGCTGCTGTAAGGG
ATAACTTCGTATAATGTATG
b) Primers used to assess integration of the PGKEM7neobpA cassette:
5' end E2f3a
1) GAAAAGAGAGAGAGAGGGTTCGG
2) TCGATATCAAGCTTATAACTCG
3' end E2f3a
1) GGTCAGGGCGCCACTTTGGAGG
2) GCCGCATAACTTCGTATAGC
5' end E2f3b
1)GGACGGTCCCGGCGCCCTCGCACC
2) CTTCCATTTGTCACGTCCTGC
3' end E2f3b
1) GGTCTTAATTAAGTCTGGGCCAAGGCACAACACGAGG
2) GCCGCATAACTTCGTATAGC
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c) Primers for gap repair retrieval of 15kb fragments from targeted BAC into pBR322:
1) GCCAATTGGATGTCTATTT'GAGAAAGAGAGGCCAGTTAGATTGTTCCAG
GACGAAAGGGCCTCGTGATACGCC
2) TCGAGTCTTGCTTACACTACCATCACGTCTGTCCTTCCGATTTCAGCCTC
CCGATACGCGAGCGAACGTGAAGC
d) Local sequence following removal of the neo cassette. ATGs shown in upper case,
loxP sequence in italics and stop codons underlined. In both cases the loxP site
contributed an in-frame stop codon.
E2f3a:
Codon number: 1 34
Wild-type: gagcgagagATG aga aag//ATG gac aaa
Mutant: gagcgagagataacttcgtatagcatacattatacgaagttatgac aaa
E2f3b:
Codon number: 1
Wild-type: ctttcggaaATG ccc tta cag cag cag
Mutant: ctttcggaaataacttcgtatagcatacattatacgaagttatccc tta cag cag cag
Southern Blotting analysis of targeted ES cells.
ES cell DNA was isolated from targeted clones as described (Laird et al., 1991)
and digested with BglII for analyses using a 676bp 5' probe (E2f3a and E2f3b) and
either SphI (E2f3a) or HindIII (E2f3b) for analyses using a 91 lbp 3' probe by Southern
blotting. A probe hybridizing to the neo cassette was also used to identify clones
containing a single insertion of the targeting construct be re-probing the 5' probe blots
following stripping of the membrane. Southern blotting was performed using Hybond N
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membranes (Amersham Biosciences, Piscataway, NJ, USA), ExpressHyb (Clontech,
Mountain View, CA USA) and standard procedures (Sambrook et al., 1989).
Radiolabeled probes were generated using a 32-P dCTP (Perkin Elmer, Waltham, MA,
USA), a Prime-It II kit (Stratagene, La Jolla, CA, USA) and purified using QuickSpin TE
columns (Roche). Five of the 240 E2f3a clones and eight of the 432 E2f3b clones were
judged to be correctly targeted.
Primers used to generate probe fragments for Southern blotting using the BAC clone
19H05 or PL452 as a template:
5' probe
1) ATCCTGCAGCTGATCAATGAGCAGGCTGGGG
2) ATCCTGCAGACTTGTTGCCAAGAGCTACACC
3' probe
1) ATCCTGCAGTGACTGGCTGTAAGCATTGTCC
2) ATCCTGCAGTACGCTAACCTGAAATACTGTCC
Neo cassette
1) GGTCGCTAGCCGGATCGGCCATTGAACAAGATGG
2) CCTCGCTAGCTGATCACTCAGAAGAACTCGTCAAGAAGGCG
Genotyping protocols for E2f3a and E2f3b mutant alleles.
Pfu polymerase (Stratagene) buffer containing 1% (E2f3a) or 5% (E2f3b) DMSO and
250nM oligonucleotides. E2f3a: Primers GGTCAGGGCGCCACTTTGGAGG and
AGCAATACGTTAATATATCGTAACAC (Integrated DNA Technologies, Coralville,
IA, USA). PCR protocol: 940C 2min; 94 TC 30s, 58 0C 30s, 72 C Imin x34 cycles, 72°C
7min. Product sizes: wild-type allele 276bp, mutant allele 210bp. E2f3b: Primers
161
CCCGGAGCCAGGCTGCTTTCGG and CCCCGTTCCCACTCCAAAACC. PCR
protocol: 94°C 2min; 94°C 30s, 62°C 30s, 720C 70s x30 cycles, 72°C 5min. Product sizes:
wild-type allele 157bp, mutant allele 188bp. E2fl genotyping was performed as described
(Cloud et al., 2002). The x2 test was used to test the null hypothesis that the frequency of
test genotypes did not deviate significantly from the predicted frequency.
Genotyping protocols for Cre recombinase expressing alleles and the loxP flanked
neo cassette prior to excision.
PCR was used to detect the presence of transgenes containing Cre.
Oligonucleotide primers were used at a final concentration of 250nM:
GAAAACGTTGATGCCGGTGAACG and GTAACAGGGTGTTATAAGCAATCC,
expected product 150bp.
PCR protocol: 940C 2min; 94 'C 30s, 55°C 30s, 72°C Imin x34 cycles, 72 0C 4min.
PCR buffer (x10): 500mM KCL, 100mM Tris pH8.5, 10mM MgCl2.
Primers used to detect the presence of the neo cassette in transgenic mice. PCR
conditions described above.
E2f3a allele: AGCAATACGTTAATATATCGTAACAC and
CTTCCATTTGTCACGTCCTGC, expected product 338bp.
E2f3b allele: CCCCGTTCCCACTCCAAAACC and
GAGGATTGGGAAGACAATAGC, expected product 286bp.
MEF generation and analyses
Passage 4 MEF lines were prepared as described (Humbert et al., 2000). Mutant
MEFs were always compared with littermate controls. Proliferation assays and cell cycle
re-entry experiments were performed essentially as described (Aslanian et al., 2004)
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apart from the determination of S-phase progression which was monitored by FACS
based detection of incorporated BrdU using a FITC conjugated anti-BrdU antibody
(347583 BD Biosciences, San Jose, CA, USA) as described (Janumyan et al., 2003),
using a BD FACScan. For Western blotting, protein extracts were prepared in 20mM
Tris pH7.5, 250mM NaCi, 5mM NaF, ImM EDTA, ImM EGTA, 1% Triton as described
using antibodies against E2f3, LLF3#2G2 (Parisi et al., 2007), pl9Arf (sc32748, Santa
Cruz Biotechnology, Santa Cruz, USA), p21Cipl (sc6246, Santa Cruz Biotechnology) and
GAPDH (4300, Ambion, Austin, TX, USA). ChIP was performed as described (Aslanian
et al., 2004). For quantitative PCR, RNA was collected from cells at 0, 12, 16, 20, and 24
hours after re-entry and RNA was processed as described (Courel et al., 2008).
Primers used for qPCR analysis:
5'-CACCGGAATCCTGGACCAG-3' and 5'-GCAGTTCGAATCTGCACCGT-3' for
Arf, 5'-GATGCTCATCTGACCGGAGT-3' and 5'-ATAAGTCACGTAGGCGCACA-3'
for p107, 5'-GACAAGAGGCCCAGTACTTCC-3' and 5'-
CAATCTGCGCTTGGAGTGATA-3' for p21, 5'-AGTTTGATAGATGCTGACCC-3'
and 5'-TAGGTCTGGTGAAGGTCC-3' for Cyclin A, 5'-
TGTTTTTGCAAGACCCAGATGA-3' and 5'-GGCTGACTGCTATCCTCGCT-3' for
Cyclin E.
Histological analyses and immunohistochemistry
Soft tissues were fixed in 3.7% formaldehyde in PBS overnight whilst adult bones
were fixed in Bouin's fixative (Poly Scientific, Bat Shore, NY, USA) for 10 days.
Paraffin sections were cut at 5 m, dewaxed and stained with hematoxylin and eosin. To
assess proliferation, femur sections from a minimum of three pairs of control and mutant
163
littermates were matched along the proximal-distal axis and immunohistochemistry was
performed using antibodies raised against Ki67 and BrdU following BrdU labeling as
described (Danielian et al., 2007). The percentage of positive nuclei was determined by
counting 150-1000 nuclei within each zone in the femoral cartilage per section and the
results analyzed by Student's t-Test. Cell area measurements were made using ImageJ
software. A minimum of 35 cells of each chondrocyte type from each femoral head were
measured and subject to the Student's t-Test and box-plot analyses. In all quantification
studies at 18.5dpc between three and six pairs of control and mutant littermates embryos
or pups were analyzed and both femurs were sectioned.
Immunohistochemistry for Collagen X and Collagen II.
For all procedures paraffin sections on slides were re-hydrated through an
ethanol series following de-waxing in xylenes and rinsed in water or PBS (phosphate
buffered saline) as required.
Collagen II: slides were washed in PBS 0.15% Triton X-100 followed by
inactivation of endogenous peroxidases by incubation with 3% H202 in PBS. Antigen
retrieval was performed by heating for 20 minutes in 10mM sodium citrate, 0.05%
Tween 20, pH6.0 in a boiling water bath. Slides were blocked with PBS containing 5%
rabbit serum and incubated overnight at 40Cwith primary antibody (sc-7764, N-19, Santa
Cruz Biotechnology) 1/500 in PBS 5% rabbit serum or this buffer alone or a non-specific
antiserum as controls. Secondary antibodies (Vectastain Elite ABC kits, Vector
laboratories) were diluted 1:200 in PBS containing 0.4% of the appropriate blocking
serum and detected using a DAB substrate following the manufacturers instructions
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(Vector Laboratories). Following the detection reaction slides were counterstained with
Harris hematoxylin and mounted using standard protocols.
Collagen X: Essentially identical to above apart from the following:
Antigen retrieval used a 0.1% pepsin, 0.5M glacial acetic acid solution for 2hrs at 370C.
Sections were washed in PBS, blocked for 2 hours in 5% horse serum in PBS
and incubated with primary antibody ColX53 (#2031501005, Quartett, Berlin, Germany)
1:20 in PBS 5% horse serum overnight at 40C. The peroxidase step was performed after
the primary antibody incubation. The remainder of the protocol is as described above.
For each marker analyzed a minimum of three pairs of control and mutant
littermate matched sections were stained and, unless stated otherwise, all scored with the
described phenotype. Images were captured on a Nikon Eclipse E600 using a SPOT
RTdigital camera.
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Supplementary Figure 2
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Figure 2: Histological analyses of femoral cartilage at 18.5dpc in E2fl;E2J3a, E2fl
and E2f3a mutant embryos.
Representative sections of the indicated control littermate (A, C and E) and mutant
embryo femurs (B, D and F) are shown. The first panel in each row x10, remainingpanels x40. Chondrocytes in E2fl;E2f3a mutants are substantially larger than normal
chondrocytes. Resting, re; columnar, co; hypertrophic hy.
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Supplementary Figure 3
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Figure 3: Collagen X and Collagen II are expressed normally in E2fmutant femurs.
Collagen X staining in (A, B) E2fl'-;E2f3a"'' (C, D) E2fl-';E2f3a/' (E, F) E2flJ' + and
(G, H) E2fl-' samples. In all cases Collagen X staining is restricted to hypertrophic
chondrocytes (arrows) and no ectopic expression in other types of chondrocytes is
observed. Collagen II expression in (I) E2fl-';E2f3a"'+ (J) E2fl';E2f3a-'- (K) E2fl'+I and
(L) E2fl' samples was detected throughout the cartilage template in all genotypes.
Panels B, D, F and H x40, remaining panels xl0.
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Appendix B
A role for RYBP in chromatin condensation
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INTRODUCTION
The polycomb group (PcG) proteins form large multimeric complexes that
influence the structure and transcriptional state of chromatin (Jacobs and van Lohuizen,
2002). PcG proteins exist in at least two distinct core polycomb repressive complexes
(PRCs) (Saurin et al., 2001; Kuzmichev et al., 2002; Levine et al., 2002). PRC2 consists
of the proteins EED, EZH, and Suzl2 (Cao et al., 2002; Kuzmichev et al., 2002; Muller
et al., 2002). This complex initiates a heritable, repressive state of chromatin through
physical modifications to the tails of histones. Specifically, EZH2 methylates histone H3
at lysine 27 (Cao et al., 2002; Czermin et al., 2002; Kuzmichev et al., 2002; Muller et al.,
2002). The PRC2 complex is necessary for targeting the PRC1 complex to genomic loci
(Cao et al., 2002). The PRC1 core complex contains the proteins Bmil, Ringla, Ringlb,
HPH, HPH2, HPC2, HPC3, and Scmhl (Saurin et al., 2001; Levine et al., 2002). Most
importantly, HPC, a homologue of the Drosophila polycomb (Pc) protein, directly binds
to methylated histone H3 at lysine 27 through a highly conserved chromodomain (Cao et
al., 2002; Muller et al., 2002). Recently, it has been found that Ringla and Ringlb have
catalytic E3 ubiquitin ligase activity towards histone H2A at lysine 119. Ring lb
maintains global H2A ubiquitination in ES cells, and both Ringla and Ringlb can
ubiquitinate histone H2A on the inactive-X chromosome (de Napoles et al., 2004; Cao et
al., 2005). The big question is whether the ubiquitin chromatin mark contributes to
repression or whether it has another function. To answer this question, Cao et. al. found
evidence that this chromatin mark participated in repression by PRCs and that H2AK119
ubiquitination is downstream of histone H3 lysine 27 methylation (Cao et al., 2005).
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Similar to the Pc protein, RYBP (Ring 1 and YY1 Binding Protein) binds directly to the
ubiquitin chromatin mark in vivo and co-localizes with Ring I a at the inactive-X
chromosome (Arrigoni et al., 2006).
RYBP interacts with YY , E2Fs, and core PRC1 components (Garcia et al.,
1999). Results from this study indicate that RYBP plays a vital role in the formation of
condensed chromatin. Additionally, there is evidence to suggest that RYBP interacts with
Suv420, a histone methyl transferase (HMTase) that methylates histone H4 at lysine 20.
The results implicate this histone methyl mark in PcG-mediated silencing and present a
vital role for RYBP in chromatin condensation.
RESULTS
Overexpression of RYBP in U-2 OS cells leads to chromatin condensation.
When expressed at low levels in a human osteosarcoma cell line (U-2 OS), RYBP
co-localizes with Bmil (Figure lA) in repressive nuclear domains termed polycomb
bodies. Endogenous E2F6, although mostly diffuse in the nucleus, also localizes to
punctate nuclear foci, suggesting that E2F6 may be present in polycomb bodies. (Figure
IB). When RYBP is overexpressed in human U-2 OS cells, genome-wide condensation is
observed (Figure 2A). These condensed chromatin "spots" have features of
heterochromatin, including histone H3 lysine 9 methylation and an absence of histone H3
acetylation (Figure 2B). These findings indicate that RYBP overexpression is causing
genome-wide reorganization of the DNA into heterochromatin.
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Figure 1: RYBP, Bmil and E2F6 localize to polycomb bodies.
(A) RYBP expressed at low levels co-localizes with Bmil in polycomb bodies. (B)
RYBP, Bmil, and E2F6 all have a punctate nuclear expression pattern.
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Figure 2: RYBP overexpression results in the formation of heterochromatin.
(A) RYBP overexpression in U-2 OS cells results in the formation of condensed
chromatin Dapi "spots." (B) The condensed chromatin have marks of heterochromatin
including H3K9 methylation and a loss of H3 acetylation.
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RYBP and Cellular Senescence
In addition to the heterochromatic changes to the DNA, the U-2 OS cells
overexpressing RYBP exhibit a senescent-like phenotype. Cellular senescence has
classically been defined as an irreversible growth arrest of cultured cells. Although the
cells remain metabolically active, they no longer respond to growth stimuli. Senescent
cells display characteristic changes in cell morphology, gene expression, and an up-
regulation of senescence-associated P3-galactosidase activity (Dimri et al., 1995). The
products of the Ink4a-Arf locus, p161NK4a and pl9', are important senescent regulators,
and they exert their effects through regulation of p53 and pRB. p16INK4a inhibits cyclin D
phosphorylation of pRB while pl9Arf promotes stabilization of p53 by inhibiting Mdm2
(Lundberg et al., 2000). Both p161NK4a and pl9" accumulate in senescent cells, and it is
believed that pRB is required for cellular senescence (Narita et al., 2003). A variety of
polycomb proteins have been shown to induce cellular senescence (Jacobs et al., 1999b;
Gil et al., 2004). In each case, the actions of these proteins require the presence of p53
and pRB (Itahana et al., 2003).
To test the requirement of p53 and pRB, we overexpressed RYBP in a human
transformed cell line, C33, which is deficient for both p53 and pRB. Overexpression of
RYBP induces chromatin condensation in C33 cells (Figure 3A), suggesting that RYBP
has a more direct role in the chromatin condensation process than any of the previously
characterized regulators. When primary human fibroblast (IMR90) cells are depleted of
RYBP by shRNA knockdown, these cells also exhibit a senescent-like morphology
(Figure 3B) and an increase in senescence-associated P-galactosidase activity (Figure
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Vector Only RYBP shRNA
Vector Only RYBP
MUTshRNA RYBP shRNA
Figure 3: RYBP chromatin condensation is independent of p53 and pRB, and
knockdown of RYBP results in cellular senescence.
(A) RYBP overexpression in cells deficient for pRB and p53 results in condensed
chromatin DAPI "spots." (B) IMR90 cells expressing a shRNA to RYBP have a cellular
morphology indicative of senescence, and (C) increased senescence-associated (3-
galactosidase activity.
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3C). No increase in senescence-associated P~-galactosidase activity is seen when the
vector alone or a point mutant shRNA is expressed in cells (Figure 3C). One hypothesis
to explain these results is that RYBP is part of the core machinery responsible for the
repression of chromatin. Overexpression of RYBP may cause heterochromatic formation
non-specifically over the entire genome, and knockdown of RYBP may cause senescence
due to the cell's inability to properly repress chromatin.
E2F6's requirement in chromatin condensation
To further investigate RYBP dependent chromatin condensation, we used
immunofluorescence to identify other proteins that are involved in this process.
Interestingly, co-expression of DP1, the E2F dimerization partner, with RYBP suppresses
the chromatin condensation (Figure 4A). These findings implicate E2F in this process.
One hypothesis is that overexpression of DPI titrates an E2F from the RYBP complex.
The most obvious candidate E2F to participate in this process is E2F6, since E2F6
interacts with RYBP and other PcG proteins (Trimarchi et al., 2001). Thus, to examine
E2F6's role in chromatin condensation, we used immunofluorescence to determine the
localization of E2F6. Endogenous (Figure 4B) and overexpressed (Figure 4C) E2F6
localizes to the condensed heterochromatin. There are two hypotheses to explain the
localization of E2F6 to the condensed chromatin: (1) E2F6 specifically participates in the
process of chromatin condensation or (2) the DNA binding activity of E2F6 localizes it to
the chromatin, but it plays no direct role in chromatin condensation. Since GFP-E2F4
does not localize to the condensed chromatin (data not shown), the second hypothesis is
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Figure 4: E2F involvement in chromatin condensation.
(A) RYBP and DP1 co-expression suppresses the chromatin condensation. (B)
Endogenous and (C) overexpressed E2F6 localizes to the condensed chromatin. (D) A
GFP-E2F6 DNA binding mutant localizes to the condensed chromatin.
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less likely to be correct. These results imply that E2F6 plays a direct role in RYBP-
mediated chromatin condensation. One possibility is that the DNA binding activity of
E2F6 recruits RYBP to the DNA. However, an E2F6 DNA binding mutant still localizes
to the condensed chromatin (Figure 4D).
Interaction of RYBP and Suv420
Suv420 methylates histone H4 at lysine 20 and acts downstream of histone H3
lysine 9 and histone H3 lysine 27 methylaiton (Schotta et al., 2004). This HMTase was
identified as an interactor of RYBP in a yeast two-hybrid screen (F Connor, JA Lees,
unpublished data). GFP-Suv420 expressed in U-2 OS cells co-localizes with RYBP in
polycomb bodies (Figure 5A). Overexpression of GFP-Suv420 results in a chromatin
condensation phenotype similar to that seen in RYBP overexpression (Figure 5B). These
results strongly suggest that RYBP interacts with Suv420, and that H4 lysine 20
methylation is involved in RYBP-mediated chromatin condensation.
DISCUSSION
Polycomb group proteins are known regulators of chromatin structure. Some PcG
proteins directly modify chromatin while others bind directly to chromatin marks.
Recently, it has been demonstrated that PRC1 can ubiquitinate histone H2A. Specifically,
Ringla and Ringlb exhibit E3 ubiquitin ligase activity towards histone H2A (de Napoles
et al., 2004; Wang et al., 2004; Cao et al., 2005). Arrigoni et al. discovered that RYBP,
another PcG protein, binds directly to ubiquitinated H2A in vivo (Arrigoni et al., 2006).
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RYBP
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Figure 5: RYBP and Suv420 co-localize to polycomb bodies, and GFP-Suv420
overexpression causes chromain condensation.
(A) GFP-Suv420 has a punctate expression pattern (first row) and co-localizes with HA-
RYBP (second row). (B) GFP-Suv420 expressed at high levels induces chromatin
condensation independently of RYBP overexpression.
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The mechanism of how the concerted action of H3K27 methylation and H2AK119
ubiquitination serves to repress chromatin is still unknown.
This study reports a novel role for RYBP in the facilitation of histone H4 lysine
20 methylation. Schotta et al. first reported H4K20 methylation to be downstream of
histone H3 lysine 9 and histone H3 lysine 27 methylation (Schotta et al., 2004). The
results presented here propose an alternate mechanism in which H2A ubiquitination and
RYBP recruits a Suv420-containing complex to PcG targets (Figure 6). This methyl mark
could lead to a very condensed state of chromatin. It is clear that a "histone code" plays a
vital role in the regulation of chromatin. PcG complexes are at the core of this regulation,
and their roles in regulation of transcription reach far beyond Hox genes.
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Figure 6: Hypothetical mechanism of
PcG Repression of Chromatin
PcG repression is initiated by PRC2 and
H3K27 methylation. This methyl mark
recruits the polycomb protein and PRC 1.
Ringl of PRC 1 ubiquitinates histone
H2A. RYBP binds directly to
ubiquitinated histones. Unpublished data
suggests that RYBP associates with a
H4K20 methylase, Suv420. This histone
methyl mark may participate in PcG
repression and lead to repressed
chromatin.
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